<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6213542</article-id><article-id pub-id-type="doi">10.3390/ijms19103063</article-id><article-id pub-id-type="publisher-id">ijms-19-03063</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Pain in Mucopolysaccharidoses: Analysis of the Problem and Possible Treatments</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2098-7896</contrib-id><name><surname>Congedi</surname><given-names>Sabrina</given-names></name><xref ref-type="aff" rid="af1-ijms-19-03063">1</xref><xref rid="c1-ijms-19-03063" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Orzalesi</surname><given-names>Marcello</given-names></name><xref ref-type="aff" rid="af2-ijms-19-03063">2</xref></contrib><contrib contrib-type="author"><name><surname>Di Pede</surname><given-names>Chiara</given-names></name><xref ref-type="aff" rid="af3-ijms-19-03063">3</xref></contrib><contrib contrib-type="author"><name><surname>Benini</surname><given-names>Franca</given-names></name><xref ref-type="aff" rid="af1-ijms-19-03063">1</xref><xref ref-type="aff" rid="af3-ijms-19-03063">3</xref></contrib></contrib-group><aff id="af1-ijms-19-03063"><label>1</label>Dipartimento di Salute della Donna e del Bambino, Universit&#x000e0; degli studi di Padova, 35128 Padua, Italy; <email>franca.benini@aopd.veneto.it</email></aff><aff id="af2-ijms-19-03063"><label>2</label>Scuola di Formazione Maruzza in Cure Palliative Pediatriche &#x0201c;Maruzza Lyceum&#x0201d;, Fondazione Maruzza Lefebvre D&#x02019;Ovidio Onlus, 00135 Rome, Italy; <email>morzalesi@interfree.it</email></aff><aff id="af3-ijms-19-03063"><label>3</label>Centro di Riferimento Veneto di Terapia del Dolore e Cure Palliative Pediatriche, Dipartimento di Salute della Donna e del Bambino, Universit&#x000e0; degli studi di Padova, 35128 Padua, Italy; <email>chiaradipede@yahoo.it</email></aff><author-notes><corresp id="c1-ijms-19-03063"><label>*</label>Correspondence: <email>sabricongedi@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>10</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2018</year></pub-date><volume>19</volume><issue>10</issue><elocation-id>3063</elocation-id><history><date date-type="received"><day>07</day><month>7</month><year>2018</year></date><date date-type="accepted"><day>02</day><month>10</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 by the authors.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Mucopolysaccharidosis (MPS) are a group of lysosomal storage disorders that are caused by the deficiency of enzymes involving in the catabolism of glycosaminoglycan (GAGs). GAGs incompletely degraded accumulate in many sites, damaging tissues and cells, leading to a variety of clinical manifestations. Many of these manifestations are painful, but few data are available in the literature concerning the prevalence, etiology, and pathogenesis of pain in children with MPS. This review, through the analysis of the data available the in literature, underscores the relevant prevalence of pain in MPSs&#x02019; children, provides the instruments to discern the etiopathogenesis of the disease and of pain, illustrates the available molecules for the management of pain and the possible advantages of non-pharmacological pain therapy in MPSs&#x02019; patients.</p></abstract><kwd-group><kwd>children</kwd><kwd>muchopolysaccaridoses</kwd><kwd>pain</kwd><kwd>treatments</kwd></kwd-group></article-meta></front><body><sec id="sec1-ijms-19-03063"><title>1. Introduction</title><p>Mucopolysaccharidoses (MPS) are a group of rare, inherited, lysosomal storage diseases that are caused by the lack, deficiency, or malfunctioning of the lysosomal enzymes involved in the degradation of complex carbohydrates known as mucopolysaccharides or glycosaminoglycans (GAGs) [<xref rid="B1-ijms-19-03063" ref-type="bibr">1</xref>]. MPS disorders are autosomal or X-linked recessive inborn errors of metabolism and they are described as inherited neurometabolic disorders (iNMDs) [<xref rid="B2-ijms-19-03063" ref-type="bibr">2</xref>]. Epidemiological studies report different data regarding MPS incidence: values of 2&#x02013;3,5 per 10.0000 live births are mostly referred [<xref rid="B3-ijms-19-03063" ref-type="bibr">3</xref>,<xref rid="B4-ijms-19-03063" ref-type="bibr">4</xref>,<xref rid="B5-ijms-19-03063" ref-type="bibr">5</xref>,<xref rid="B6-ijms-19-03063" ref-type="bibr">6</xref>,<xref rid="B7-ijms-19-03063" ref-type="bibr">7</xref>].</p><p>Patients with MPS are characterized by the accumulation of incompletely degraded GAGs in multiple sites that results in severe clinical manifestations and premature death. The storage products cause a cascade of events, leading to the progressive damage of cells, tissues, and organ systems. Most patients with MPS have a normal appearance at birth, but the progressive storage of GAGs in cells leads to a wide range of clinical manifestations. The lacking or non-functioning enzymes impact on the child&#x02019;s growth and on the nervous system development from birth to adulthood, causing severe and irreversible neurological manifestations. Clinical features include facial dysmorphisms, dental abnormalities, hearing loss, ophthalmogical manifestations, joint and bone disease, cardiorespiratory problems, gastro-intestinal disorders, neurogical problems, and cognitive impairment [<xref rid="B8-ijms-19-03063" ref-type="bibr">8</xref>]. The different types of MPS have been historically numbered from I to IX (<xref rid="ijms-19-03063-t001" ref-type="table">Table 1</xref>): even if the clinical features are largely comparable, a wide range of phenotypes, different progression velocities, and grades of severity are reported for each type. </p><p>In absence of specific treatments premature death occurs in most patients with MPS [<xref rid="B9-ijms-19-03063" ref-type="bibr">9</xref>].</p><p>Cognitive delay is present in patients with MPS I type (or Hurler Syndrome), MPS III type (or Sanfilippo syndrome), and in the more severe form of MPS II (Hunter Syndrome) [<xref rid="B1-ijms-19-03063" ref-type="bibr">1</xref>].</p><p>MPS is usually suspected clinically in early childhood and the diagnosis is confirmed by molecular biochemical analysis. The genetic analysis can identify a variety of different mutations for the genes involved, as well as carriers and new variants of unknown significance [<xref rid="B10-ijms-19-03063" ref-type="bibr">10</xref>]. A timely diagnosis of MPS allows for planning an early global intervention and to prevent irreversible damages. From the time of diagnosis, a multidisciplinary approach should be undertaken, including clinical and psychological aspects and support to the patients and their families. Treatment options currently available are intended to guarantee a better quality of life, particularly when healing the disease is impossible. Specific enzyme replacement therapy (ERT) has been approved and it is currently available for MPS I, II, IVA, and VI, but only MPS IVa is treatable by ERT [<xref rid="B11-ijms-19-03063" ref-type="bibr">11</xref>,<xref rid="B12-ijms-19-03063" ref-type="bibr">12</xref>,<xref rid="B13-ijms-19-03063" ref-type="bibr">13</xref>], and hematopoietic stem cell therapy (HSCT) is the main therapeutic option for MPS I Hurler patients under 2.5 years old [<xref rid="B14-ijms-19-03063" ref-type="bibr">14</xref>]. </p><p>In MPS patients, with and without cognitive impairment, pain is a common feature but it is still often unsuspected, poorly assessed, and undertreated. Few studies have fully assessed the prevalence of pain and its impact on the quality of life in this population. In the less recent literature, pain was considered only as a possible outcome measure of successful ERT) [<xref rid="B15-ijms-19-03063" ref-type="bibr">15</xref>,<xref rid="B16-ijms-19-03063" ref-type="bibr">16</xref>]. Brands et al. [<xref rid="B11-ijms-19-03063" ref-type="bibr">11</xref>], examined pain prevalence in paediatric patients with all types of MPS. They conducted a survey in the Netherlands using questionnaires to evaluate different aspects of the disease: symptoms, developmental and disability level, and quality of life. In this study, pain was also evaluated in MPS patients with intellectual disability and a higher pain prevalence was reported (according to this survey, up to 53% of MPS patients with cognitive delay and only 30% of patients with a normal intelligence experienced pain) [<xref rid="B11-ijms-19-03063" ref-type="bibr">11</xref>].</p><p>In this study we present a systematic review of the current knowledge regarding mucopolysaccharidosis in children, with the purpose to discuss etiopathogenesis and clinical features of the disease, paying particular attention to pain. In particular, we discuss the possible etiopathogenesis of pain and its pharmacological and non-pharmacological management.</p></sec><sec id="sec2-ijms-19-03063"><title>2. Etiopathogenesis of the Disease</title><p>In order to explain and understand the etiology of MPS, studies on animal models have been conducted revealing massive storage of GAGs in liver, kidney, lung, spleen and brain [<xref rid="B17-ijms-19-03063" ref-type="bibr">17</xref>,<xref rid="B18-ijms-19-03063" ref-type="bibr">18</xref>,<xref rid="B19-ijms-19-03063" ref-type="bibr">19</xref>]. Moreover, GAGs were also found in the trabecular matrix and bone cortex [<xref rid="B20-ijms-19-03063" ref-type="bibr">20</xref>].</p><p>Many authors have investigated the specific pathways that are altered in MPSs: Lysosomal enzymes activity, gangliosides and cholesterol metabolism, and inflammation. In MPS I, MPS II, MPS III and MPS VII many authors have confirmed how the deficiency of a lysosomal hydrolase can lead to the imbalance of other lysosomal enzymes activity. This could be explained by the influence of a large mass of lysosomes in cells or by the stabilisation of enzymes by the storage material. Previous works revealed an increased activity of &#x003b2;-hexosaminidase, &#x003b1;-glucosidase, &#x003b2;-galactosidase, and &#x003b2;-gluronidase enzymes in tissues, such as liver and brain, while sialidase (also known as neuraminidase) and <italic>N</italic>-acetylglucosaminyltransferase were less active. In humans affected by MPS I, MPS II, and MPS IIIA, a significant alteration of ganglioside metabolism was also described: accumulation of glycosphingolipids, most notably GM2 and GM3 gangliosides, were reported [<xref rid="B21-ijms-19-03063" ref-type="bibr">21</xref>,<xref rid="B22-ijms-19-03063" ref-type="bibr">22</xref>,<xref rid="B23-ijms-19-03063" ref-type="bibr">23</xref>]. This surprising feature was studied in animal models with MPS I, MPS II, MPS IIIA, MPS IIIB, MPS IIID, and MPS VI [<xref rid="B18-ijms-19-03063" ref-type="bibr">18</xref>,<xref rid="B20-ijms-19-03063" ref-type="bibr">20</xref>,<xref rid="B23-ijms-19-03063" ref-type="bibr">23</xref>,<xref rid="B24-ijms-19-03063" ref-type="bibr">24</xref>,<xref rid="B25-ijms-19-03063" ref-type="bibr">25</xref>]. These studies suggest that glycosphingolipids storage is found in the early stage of the disease and it is one of the main elements that is involved in central nervous system (CNS) damage, causing alterations of dendritic cells, of axonal morphology, and of synapses. As a consequence, the ectopic dendritogenesis can lead to the formation of the so called &#x0201c;meganeurite&#x0201d; (a swollen section of the axon). These alterations are frequently observed in gangliosidosis, such as Tay-Sachs and Niemann-Pick [<xref rid="B25-ijms-19-03063" ref-type="bibr">25</xref>,<xref rid="B26-ijms-19-03063" ref-type="bibr">26</xref>,<xref rid="B27-ijms-19-03063" ref-type="bibr">27</xref>].</p><p>Recent papers reported another feature in murine models of MPS I, MPS IIIA, and MPS IIIB: the accumulation of free unesterified cholesterol in neurons, secondary to ganglioside storage [<xref rid="B26-ijms-19-03063" ref-type="bibr">26</xref>]. The altered intracellular distribution of cholesterol found in Niemann&#x02013;Pick disease C [<xref rid="B27-ijms-19-03063" ref-type="bibr">27</xref>] and glycosphingolipidoses GM2 [<xref rid="B28-ijms-19-03063" ref-type="bibr">28</xref>] leads to a defective transport of glycosphingolipids; the accumulation of these molecules could explain the sequestration of membrane rafts and contribute to neurological damage [<xref rid="B27-ijms-19-03063" ref-type="bibr">27</xref>,<xref rid="B28-ijms-19-03063" ref-type="bibr">28</xref>]. Recently, inflammatory responses have been described as a prominent component of MPS disease. Inflammatory cascade in MPS I and MPS IIIB has been reported as a possible cause of CNS damage [<xref rid="B29-ijms-19-03063" ref-type="bibr">29</xref>]; many elements are involved in this process (perineuronal microglial activation, increment of transcripts for CD38, lysozyme M, cathepsins S and Z, cytochrome b558, DAP12, and complements C1q and C4), all being related to an exaggerated macrophage/monocyte activation [<xref rid="B30-ijms-19-03063" ref-type="bibr">30</xref>]. Evidence of the role of inflammation cascade has also been reported for bone and joint disease in MPSs. Musculoskeletal problems are prominent features in MPSs; even if no clinical signs of joint inflammation are present, previous studies conducted on animal models of MPSs I, II, VI, and VII reported local, intracellular inflammation due to dermatan sulfate storage.</p><p>Anatomopathological elements of cartilage apoptosis, synovial hyperplasia, recruitment of macrophages, altered connective tissue matrices, and inflammatory joint destruction are described in MPS patients as a consequence of dermatan sulfate accumulation. These damages are produced by dermatan sulfate storages through intracellular inflammation, alteration of growth of connective tissue and other cells, production and release of inflammatory cytokines, chemokines, proteases, and nitric oxide that induce the production of proapoptotic lipid ceramide [<xref rid="B31-ijms-19-03063" ref-type="bibr">31</xref>,<xref rid="B32-ijms-19-03063" ref-type="bibr">32</xref>]. Moreover, animal studies indicate that GAGs can inhibit collagenase activity of cathepsin K, with an alteration of chondrocyte maturation, mineralization, and osteoblast differentiation [<xref rid="B33-ijms-19-03063" ref-type="bibr">33</xref>].</p></sec><sec id="sec3-ijms-19-03063"><title>3. Etiopathogenesis of Pain</title><p>Pain is a common feature in MPS patients, but it is still inadequately assessed and undertreated. Few data are available on the physiopathology and epidemiology of pain in MPS children. We carried out a PubMed search of the literature while using the following mesh terms &#x0201c;&#x0201c;Pain/pathology&#x0201d; [Mesh] AND &#x0201c;Mucopolysaccharidoses&#x0201d;&#x0201d; and two items were obtained. When picking age filters and choosing the category &#x0201c;children: birth-18 years&#x0201d;, we did not find any publication.</p><p>In general, pain is typically classified into three major categories, applied for both adults and children: nociceptive (somatic or visceral), neuropathic and mixed [<xref rid="B34-ijms-19-03063" ref-type="bibr">34</xref>].</p><p>Nociceptive pain (NOP) is due to the direct involvement of somatic superficial or deep tissue or visceral structures. This pain is referred as well localized with different characteristics due to its origin; it could be described as a fixed deep or as an acute stabbed pain. A review on lysosomal diseases [<xref rid="B34-ijms-19-03063" ref-type="bibr">34</xref>] reported joint stiffness as a hallmark of almost all MPS, from mild-moderate forms to severe ones. This manifestation, which is not present in MPS IV and MPS IX [<xref rid="B35-ijms-19-03063" ref-type="bibr">35</xref>], is probably due to GAGs storage in ligaments, tendons, joint capsules, and other soft tissues along with epiphyseal and metaphyseal deformities [<xref rid="B7-ijms-19-03063" ref-type="bibr">7</xref>]. Joint swelling is frequently associated with joint stiffness and is due to bone enlargement [<xref rid="B35-ijms-19-03063" ref-type="bibr">35</xref>]. This is an example of nociceptive somatic pain that is frequently reported in children with MPS; it could be caused by tissue injury or inflammation [<xref rid="B36-ijms-19-03063" ref-type="bibr">36</xref>]. Nociceptive free-nerve endings and neuropeptides, such as substance-P, which is present in many articular and peri-articular tissues (accessory ligaments, synovium, subchondral bone, menisci, and periosteum) are the mediators that are involved in the origin of joint pain. Trigger finger, also known as stenosing tenosynovitis, caused by GAGs storage in the capsular tissues of joints or flexor tendons is frequently reported in MPS patients [<xref rid="B37-ijms-19-03063" ref-type="bibr">37</xref>,<xref rid="B38-ijms-19-03063" ref-type="bibr">38</xref>]. A role of the vascular system in pain generation, through vasospasm or ischemia, has been proposed but has yet to be proven [<xref rid="B39-ijms-19-03063" ref-type="bibr">39</xref>]. Angina pectoris in children and infants has also been reported as a feature of MPS (Hurler&#x02019;s syndrome) [<xref rid="B40-ijms-19-03063" ref-type="bibr">40</xref>]. Indeed, in these patients a coronary arterial obstruction could be observed due to luminal narrowing and thickening of the arterial wall by partially degraded GAGs [<xref rid="B41-ijms-19-03063" ref-type="bibr">41</xref>]. Another possible cause of visceral pain in MPS children is hepatomegaly or hepato-splenomegaly, being due to the abnormal accumulation of partially degraded GAGs [<xref rid="B8-ijms-19-03063" ref-type="bibr">8</xref>,<xref rid="B35-ijms-19-03063" ref-type="bibr">35</xref>,<xref rid="B42-ijms-19-03063" ref-type="bibr">42</xref>].</p><p>Neuropathic pain (NP) is caused by injury, inflammation, or dysfunction of the peripheral or central nervous systems [<xref rid="B43-ijms-19-03063" ref-type="bibr">43</xref>,<xref rid="B44-ijms-19-03063" ref-type="bibr">44</xref>]; more specifically, it is secondary to the continuous stimulation of nociceptors as a result of chronic inflammation [<xref rid="B45-ijms-19-03063" ref-type="bibr">45</xref>]. NP is referred as a stinging, stabbing pain, like a feeling of pins, associated to tingling and hyperalgesia, hyperaesthesia, and allodynia; it does not successfully respond to opioids, while anti-depressants (amitriptyline, nortriptyline) and anticonvulsant drugs (carbamazepine, gabapentin) are efficacious. Neuropathic pain is a common symptom associated with peripheral neuropathy and carpal tunnel syndrome can be a possible cause of neuropathic pain in MPS patients. Carpal tunnel syndrome is defined as an entrapment neuropathy of the median nerve at the wrist [<xref rid="B46-ijms-19-03063" ref-type="bibr">46</xref>] and classic symptoms include numbness and paresthesias in the radial three-and-half-fingers of the hand, and motor weakness of the thenar muscles. These alterations in MPS patients are due to the compression of the median nerve due to thickening of the flexor retinaculum and the tissues around the nerve sheaths [<xref rid="B47-ijms-19-03063" ref-type="bibr">47</xref>].</p><p>In patients that are affected by MPS, spinal cord injuries (SCI) are frequently reported: cervical myelopathy, paraplegia, and sudden death could be consequences of cervical stenosis and instability, due to hypoplasia, ligamentous laxity, incomplete ossification of vertebrae and extradural GAGs deposition [<xref rid="B48-ijms-19-03063" ref-type="bibr">48</xref>]. Patients with SCI often develop chronic neuropathic pain [<xref rid="B49-ijms-19-03063" ref-type="bibr">49</xref>]. Endothelin peptides, which exert their effects via endothelin A (ETAR) and endothelin B (ETBR) receptors, can contribute to this pain through an increased neuronal excitability in somatosensory pathways [<xref rid="B50-ijms-19-03063" ref-type="bibr">50</xref>,<xref rid="B51-ijms-19-03063" ref-type="bibr">51</xref>,<xref rid="B52-ijms-19-03063" ref-type="bibr">52</xref>].</p></sec><sec id="sec4-ijms-19-03063"><title>4. Epidemiology of Pain</title><p>Pain, in general, is a common symptom in children and adolescents, ranging from 20% to 46% individuals worldwide [<xref rid="B53-ijms-19-03063" ref-type="bibr">53</xref>]. Pain is also common in MPS patients with and without cognitive impairment, but few data are available about its real frequency, probably because it is poorly assessed. The underestimation of pain in this population can be explained, at least in part, by a difficult clinical evaluation due to the complexity of the disease and the presence of cognitive impairment [<xref rid="B54-ijms-19-03063" ref-type="bibr">54</xref>].</p><p>Musculo-skeletal problems are very common in MPS patients, mainly in type I, II, III, VI, and VII; joint alterations and skeletal deformities generally develop in the early-stages of the disorder [<xref rid="B35-ijms-19-03063" ref-type="bibr">35</xref>,<xref rid="B55-ijms-19-03063" ref-type="bibr">55</xref>,<xref rid="B56-ijms-19-03063" ref-type="bibr">56</xref>]. In a survey that was conducted by Brands [<xref rid="B11-ijms-19-03063" ref-type="bibr">11</xref>] and colleagues, the frequency and type of pain were investigated through questionnaires administered to children affected by different types of MPSs; in this group a pain score above the critical cut-off value for significant pain was reported in 40% of cases. The highest frequency of pain was observed in the MPS III group (52.9%); more than half of patients experienced joint pain (69%), mainly hip and back pain (27.8% and 25.9%, respectively). In a patient-reported outcome survey that was conducted by Hendriksz and colleagues [<xref rid="B57-ijms-19-03063" ref-type="bibr">57</xref>], the impact of Morquio A syndrome (or MPSIVA) on adult and paediatric patients&#x02019; life was evaluated. The aims of the study were to evaluate quality of life, mobility, pain and fatigue. Joint pain was experienced by 64% of children and was inversely related to the intensity of wheelchair use. Those who frequently used a wheelchair reported less intense and less frequent pain than those using a wheelchair sporadically. The impact of wheelchair use on pain and fatigue followed a specific pattern: better mobility was associated with more pain and more fatigue. Hendriksz et al. identified in a better pain management and in the maintenance of functional capacity, elements that can significantly improve the quality of life in MPS patients [<xref rid="B57-ijms-19-03063" ref-type="bibr">57</xref>].</p><p>Pain was also considered as an outcome measure in Morquio A patients by Burton et al. [<xref rid="B58-ijms-19-03063" ref-type="bibr">58</xref>], who utilized the Word Graphic Rating Scale (WGRS), a visual analog scale (from 0 to 10): at baseline, a pain intensity score of 4.6 was reported. Musculoskeletal alterations are not usually considered principal features in MPS III patients, which are mainly characterized by neurodegenerative manifestations. However, although musculoskeletal manifestations are less severe in these patients, many families required an orthopaedic evaluation for the perceived musculoskeletal discomfort of hips and spine [<xref rid="B59-ijms-19-03063" ref-type="bibr">59</xref>,<xref rid="B60-ijms-19-03063" ref-type="bibr">60</xref>].</p><p>In the study published by White et al., several patients were referred to their service for hip pain, frequently associated with osteonecrosis of the femoral head (ONFH) [<xref rid="B60-ijms-19-03063" ref-type="bibr">60</xref>]. De Ruijter et al. conducted a radiographic study in a group of MPS III patients, reporting a high prevalence of ONFH: Signs of ONFH were detected in eight patients (24%) and most of them (87%) referred hip pain [<xref rid="B59-ijms-19-03063" ref-type="bibr">59</xref>]. Musculoskeletal problems, causing significant morbidity, were investigated by Vijay and Wraith [<xref rid="B42-ijms-19-03063" ref-type="bibr">42</xref>] in a sample of 29 children with attenuated MPSI phenotype; in this survey, bone abnormalities were the prominent features at presentation and during the course of the disease (i.e., Hurler-Scheie or Scheie). Progressive arthropathy (86%), in particular located at the interphalangeal joints, with fixed flexion deformities of fingers (24%), was present; spine deformities such as gibbus (21%), kyphosis, scoliosis, and/or lordosis (24%) were also detected; carpal tunnel syndrome was present in more than half of patients (66%); recurrent ear, nose, throat (62%); and, airway inflammation (31%) were also found. All these manifestations are possible and concrete causes of pain; nevertheless, this symptom is not well investigated and extensive data are lacking.</p><p>Skeletal deformities, such as coxa valga and genua valga, are typical, frequent, and painful abnormalities in MPS patients, but no prevalence data are available [<xref rid="B61-ijms-19-03063" ref-type="bibr">61</xref>]. Carpal tunnel syndrome (CTS) in children is strongly suggestive of MPS or mucolipidosis [<xref rid="B62-ijms-19-03063" ref-type="bibr">62</xref>,<xref rid="B63-ijms-19-03063" ref-type="bibr">63</xref>,<xref rid="B64-ijms-19-03063" ref-type="bibr">64</xref>]. Hand pain, numbness, paresthesias, and a feeling of weakness in hand grip are the principal symptoms referred by children [<xref rid="B65-ijms-19-03063" ref-type="bibr">65</xref>]. Cervical myelopathy and paraplegia must be always considered as possible painful conditions in MPS and they have been well documented in MPS IVA [<xref rid="B66-ijms-19-03063" ref-type="bibr">66</xref>,<xref rid="B67-ijms-19-03063" ref-type="bibr">67</xref>]. These conditions can be due to the undertreatment of upper cervical stenosis and instability and a prompt evaluation is needed in order to avoid severe nerve damage.</p><p>An interesting aspect is pain in MPS children with cognitive impairment; pain is more frequently reported in this group when compared to the group of children with normal intelligence. In the survey by Brands and colleagues, half of the mentally disabled patients presented pain compared to a third of children without a cognitive disability [<xref rid="B11-ijms-19-03063" ref-type="bibr">11</xref>]. The high prevalence of pain in disabled children has been confirmed by other publications [<xref rid="B68-ijms-19-03063" ref-type="bibr">68</xref>,<xref rid="B69-ijms-19-03063" ref-type="bibr">69</xref>,<xref rid="B70-ijms-19-03063" ref-type="bibr">70</xref>,<xref rid="B71-ijms-19-03063" ref-type="bibr">71</xref>]. This high prevalence of pain in cognitively impaired patients could even be underestimated due to the difficulties of assessing pain in this particular population. The assessment and measurement of pain in children with cognitive delay must be performed utilizing pain scales validated for this specific population. Among the numerous tools available, the r-FLACC scale is preferred by parents and health workers [<xref rid="B72-ijms-19-03063" ref-type="bibr">72</xref>,<xref rid="B73-ijms-19-03063" ref-type="bibr">73</xref>].</p></sec><sec id="sec5-ijms-19-03063"><title>5. Pharmacological Therapy</title><p>Children with MPS live with chronic pain and severe disability. Therefore, an adequate assessment and management of pain should be an essential component of paediatric care. MPS patients experience different types of pain (nociceptive, neuropathic, mixed) related to complications of the disease: skeletal deformities, muscular stiffness, compression of neural elements, and the compression of visceral organs. The main goals of paediatric pain management are the control pain and the improvement of the quality of life of children and their families.</p><p>Currently, two options are available: the treatment of the disease and the management of pain symptom. ERT and HSCT are the two available options that target the pathophysiological mechanism of MPS. The effect of HSCT on the patients&#x02019; reported health related quality of life has not been adequately addressed to date [<xref rid="B74-ijms-19-03063" ref-type="bibr">74</xref>,<xref rid="B75-ijms-19-03063" ref-type="bibr">75</xref>]. MPS patients (in particular, I, IVa, and VI) treated with ERT reported pain reduction and improvement in their quality of life and daily activities [<xref rid="B13-ijms-19-03063" ref-type="bibr">13</xref>,<xref rid="B16-ijms-19-03063" ref-type="bibr">16</xref>,<xref rid="B76-ijms-19-03063" ref-type="bibr">76</xref>,<xref rid="B77-ijms-19-03063" ref-type="bibr">77</xref>].</p><p>Laronidase (recombinant human alpha L iduronidase) is approved by the FDA as a specific therapy for MPSI. The approval of laronidasi is based on a phase III study on MPSI, in which patients were randomized to weekly intravenous infusions of laronidasi or placebo. After 26 weeks of treatment, patients in the laronidase group showed improved forced vital capacity and walking distance, and reduced hepatomegaly and GAGs as compared to the placebo group. In addition, laronidasi improved sleep apnea and shoulder mobility [<xref rid="B78-ijms-19-03063" ref-type="bibr">78</xref>].</p><p>Gasulfase (recombinant human-acetylgalactosamine-4-sulftase) is approved by the FDA as a specific therapy for MPS VI [<xref rid="B79-ijms-19-03063" ref-type="bibr">79</xref>]. This drug was administered once weekly and led to decreased urinary GAGs together with function improvement and prolonged survival [<xref rid="B80-ijms-19-03063" ref-type="bibr">80</xref>]. In an open label phase II trial, patients who received weekly infusions for 48 weeks responded with improved endurance and decreased pain when compared with their baseline [<xref rid="B14-ijms-19-03063" ref-type="bibr">14</xref>].</p><p>There is a critical need to understand the mechanism of chronic pain in MPS in order to improve its treatment. A potential target is inflammation. Animal studies suggest a possible role of tumor-necrosis factor-alpha (TNF-alpha) antagonists [<xref rid="B31-ijms-19-03063" ref-type="bibr">31</xref>]. Polgreen et al. demonstrated that higher TNF-alpha levels are implicated in pain [<xref rid="B81-ijms-19-03063" ref-type="bibr">81</xref>]. In their five-years prospective longitudinal study, 55 patients with MPSI, II and VI were enrolled and annually evaluated; 51 healthy controls were enrolled in a separated cross-sectional study of bone and energy metabolism. Pain and disability were evaluated through the Children&#x02019;s Health Questionnaire-Parent Form 50 (CHQ-PF50). TNF-alpha levels were measured in 48 MPS (22 treated with HSCT, 24 with ERT) and in 51 controls. TNF-alpha levels were higher in MPS when compared with controls. Higher TNF-alpha levels were associated with increased pain and decreased physical function. This study suggests that anti TNF-alpha agents could be a useful adjunctive therapy of pain. Both non-opioid and opioid drugs are currently used in paediatric pain control (<xref rid="ijms-19-03063-t002" ref-type="table">Table 2</xref>). The choice of analgesic is usually based on the type, source, severity, and duration of pain; personal experience can otherwise influence the choice.</p><p>Non-opioid analgesics include Acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs). These drugs are used in children with mild pain, but they can be used in association with opioids to treat moderate and severe pain. Acetaminophen is the most widely used antipyretic and analgesic drug for mild pain treatment, because it is generally free of adverse effects when administered in appropriate therapeutic doses. Nonsteroidal anti-inflammatory drugs (NSAIDs) include a group of molecules with different analgesic power. A powerful NSAID drug is Ketorolac, efficient in severe pain, such as renal colics and bone fractures; it should be used for short periods for the high risk of side effects. Ketorolac has a reversible inhibitory effect on platelet aggregation and it can cause dose-related gastric ulcerations, even when administered parenterally.</p><p>Less side effects were reported for NSAIDs with intermediate power, like Naproxene, Diclofenac, and Piroxicam: all of these drugs have similar safety profiles. They are frequently used to treat moderate pain, particularly osteoarticular pain, headache, and migraine attacks. Finally, Ibuprofen and Ketoprofen are NSAIDs with less power and should be prescribed for mild and moderate inflammatory pain.</p><p>Ibuprofen is the most utilized NSAID in children. Ibuprofen may be more effective than Acetaminophen in those situations in which inflammation is the major cause of pain. The use of Aspirin has been restricted because of its association with Reye&#x02019;s syndrome.</p><p>Opioids are generally used in children with moderate and severe pain. Opioids have opium or morphine-like properties. They interact with one or more of the four identified opiate receptors of the central nervous system, resulting in a reduction of perceived pain. The selection of the specific opioid depends on the type, intensity, and duration of pain; in children with chronic moderate pain a weak oral opioid (e.g., Tramadol) or long-acting stronger opioids at low oral doses (e.g., Oxycodone or Methadone) can be used. Children with more severe pain need to be treated with strong opioids, such as Morphine, Oxycodone, or Fentanyl. Morphine is generally administered in children with episodic severe pain, while a sustained release preparation or agents with a long half-life (e.g., Oral Methadone) should be used if severe pain becomes chronic (e.g., Oxicontin or Transdermal Fentanyl).</p><p>A fearsome form of chronic pain is neuropathic pain, because it is often refractory to conventional pharmacotherapies. Adjuvant therapies, including antidepressants (Tricyclic) and anticonvulsants (Gabapentin and Carbamazepine), can be very helpful in treating neuropathic and mixed pain in children with MPS. This therapy has the goal to treat visceral hyperalgesia, central and peripheral neuropathic pain [<xref rid="B82-ijms-19-03063" ref-type="bibr">82</xref>,<xref rid="B83-ijms-19-03063" ref-type="bibr">83</xref>].</p><p>Glucocorticoids can be successfully utilized to treat pain deriving from hepatic distension; Bisphosphonates are used to treat pain from bone fractures.</p><p>Cannabinoids have been used for pain relief for centuries, although poor knowledge was available regarding their mechanism. In the last two decades, the efficacy of Cannabinoids in treating neuropathic pain has been tested in animal models and relevant information was obtained after the discovery of cannabinoid receptors and their endogenous ligands [<xref rid="B84-ijms-19-03063" ref-type="bibr">84</xref>,<xref rid="B85-ijms-19-03063" ref-type="bibr">85</xref>]. At present, the main evidence-based clinical use of Cannabinoids concerns adult patients with different types of pain, such as refractory chemotherapy-related nausea and neuropathy [<xref rid="B86-ijms-19-03063" ref-type="bibr">86</xref>], neuropathic pain, spasticity in multiple sclerosis [<xref rid="B87-ijms-19-03063" ref-type="bibr">87</xref>], and AIDS-related neuropathy [<xref rid="B88-ijms-19-03063" ref-type="bibr">88</xref>]. Few good quality randomized trials indicate that Cannabinoids are an effective and safe treatment option for chronic non-cancer (predominantly neuropathic) pain [<xref rid="B89-ijms-19-03063" ref-type="bibr">89</xref>,<xref rid="B90-ijms-19-03063" ref-type="bibr">90</xref>].</p><p>Few papers reported positive and negative effects of Cannabinoids use for chronic pain in adults, and there are even less data for the paediatric population. Notwithstanding the benefits reported, adverse physiological and physical effects (psychomotor and cognitive impairment, anxiety and panic attacks, acute psychosis and paranoia, dry mouth, blurred vision, palpitations, tachycardia, and postural hypotension) may limit their therapeutic use in children [<xref rid="B91-ijms-19-03063" ref-type="bibr">91</xref>,<xref rid="B92-ijms-19-03063" ref-type="bibr">92</xref>].</p></sec><sec id="sec6-ijms-19-03063"><title>6. Non-Phamarcological Therapies</title><p>Pain has negative effects on all aspects of health-related quality of life, including physical, emotional, social, and role functioning [<xref rid="B93-ijms-19-03063" ref-type="bibr">93</xref>]; high levels of pain are often associated with anxiety and depression [<xref rid="B94-ijms-19-03063" ref-type="bibr">94</xref>,<xref rid="B95-ijms-19-03063" ref-type="bibr">95</xref>].</p><p>Even if there are significant gaps in the existing literature on non-pharmacological management of pain, positive results are reported. Non-pharmacological therapies should be taken into consideration in addition to the pharmacological ones mostly for illness associated emotional, social, and spiritual disturbances and in the case of chronic pain [<xref rid="B96-ijms-19-03063" ref-type="bibr">96</xref>]. Although non-pharmacologic techniques can be proposed as stand-alone treatments, they are often used in a multimodal therapy background, with the aim to make pain control more effective [<xref rid="B97-ijms-19-03063" ref-type="bibr">97</xref>].</p><p>Non-pharmacological treatments may be classified, as follows: (i) psychological interventions (distraction, stress management, hypnosis, and other cognitive-behavioural interventions); (ii) acupuncture and acupressure; (iii) transcutaneous electrical nerve stimulation (TENS); and, (iv) physical therapies (including massage, heat/cold, physiotherapy, osteopathy, and chiropractic).</p><p>Psychological therapies can be delivered individually or in groups to children and their families [<xref rid="B98-ijms-19-03063" ref-type="bibr">98</xref>], and they are effective in reducing pain intensity and disability in children with chronic pain. The psychological approaches for pain management include cognitive-behavioural therapy, self-regulation strategies (hypnosis and biofeedback techniques, interventions aimed at producing behavioural changes, psychosocial support [<xref rid="B29-ijms-19-03063" ref-type="bibr">29</xref>,<xref rid="B30-ijms-19-03063" ref-type="bibr">30</xref>]), and educational programs.</p><p>Strategies, such as distraction, relaxation, breathing, visualization, imagery, modifying cognitive distortions, desensitisation, and changing negative thinking into positive ones should be thought to patients, to cope with their pain [<xref rid="B99-ijms-19-03063" ref-type="bibr">99</xref>]. In order to successfully include psychosocial interventions in pain management, several barriers must be removed. First of all, patients and their parents should establish and maintain a good relationship with the health care providers. It is also necessary to be aware that cultural and financial factors play a principal role for the effectiveness of psychosocial interventions [<xref rid="B100-ijms-19-03063" ref-type="bibr">100</xref>,<xref rid="B101-ijms-19-03063" ref-type="bibr">101</xref>]. Cultural differences strongly influence the pain behaviour in individuals (it could be emotional, stoic, demanding, or vague) and also the frequency of administration of pain medications [<xref rid="B102-ijms-19-03063" ref-type="bibr">102</xref>].</p><p>Acupuncture is the stimulation of specific points on the body and it is widely recognized as a therapeutic procedure to treat osteoarticular pain in adults [<xref rid="B103-ijms-19-03063" ref-type="bibr">103</xref>,<xref rid="B104-ijms-19-03063" ref-type="bibr">104</xref>].</p><p>The efficacy of acupuncture in the treatment of different conditions in children, such as migraines, abdominal pain, fibromyalgia and complex pain regional syndrome has been reported in two studies [<xref rid="B105-ijms-19-03063" ref-type="bibr">105</xref>,<xref rid="B106-ijms-19-03063" ref-type="bibr">106</xref>]. Electroacupuncture and acupressure are treatments based on acupoint stimulation: the first technique requires the delivery of electrical current through a needle; the second one requires acupoints stimulation through fingers and hands. Analgesia in acupuncture is realized through the modulation in central descending pain pathways (nucleus raphe magnus), influencing the release of endogenous peptides; the involvement of noradrenergic receptors has also been demonstrated in animal models [<xref rid="B107-ijms-19-03063" ref-type="bibr">107</xref>,<xref rid="B108-ijms-19-03063" ref-type="bibr">108</xref>].</p><p>In TENS, the nerves are stimulated by an electric current that is produced by a portable device inducing activation of non-nociceptive fibers thus obtaining pain relief (gate control therapy). Among physical therapies, many studies confirm the successful role of warming in treating acute and chronic pain: it can decrease the intensity of pain, anxiety, heart rate, and increase the pain threshold [<xref rid="B109-ijms-19-03063" ref-type="bibr">109</xref>,<xref rid="B110-ijms-19-03063" ref-type="bibr">110</xref>]. Positive results, such as reduction of anxiety and pain intensity, have been reported for massage and chiropratic interventions in children [<xref rid="B111-ijms-19-03063" ref-type="bibr">111</xref>,<xref rid="B112-ijms-19-03063" ref-type="bibr">112</xref>]. Few data are available regarding the effectiveness of music therapy in pain management: it has been used with positive results as part of multidisciplinary approach to treat chronic pain in children [<xref rid="B113-ijms-19-03063" ref-type="bibr">113</xref>,<xref rid="B114-ijms-19-03063" ref-type="bibr">114</xref>]. Among alternative therapies, an emerging strategy in pain control is the animal assisted therapy (AAT). A number of studies have suggested a positive effect of AAT in different health care settings but much less on pain in children. Braun et al. and Sobo et al. studied AAT and pain perception in children, finding a significant decrease in pain levels [<xref rid="B115-ijms-19-03063" ref-type="bibr">115</xref>,<xref rid="B116-ijms-19-03063" ref-type="bibr">116</xref>]. Further research is needed to prove the potential value of complementary therapies and their applicability in paediatric pain.</p></sec><sec id="sec7-ijms-19-03063"><title>7. Surgical Treatment</title><p>During lifetime and from the early stages up to 75% of patients with MPS may need emergency or elective surgical interventions. However, surgery can only improve the signs of MPS disease expression due to GAGs&#x02019; tissue accumulation and not to effectively treat the disorder. Due to a variety of musculo-skeletal problems, MPS pediatric patients may benefit from a surgical approach to solve CPS, hip displasya [<xref rid="B117-ijms-19-03063" ref-type="bibr">117</xref>], trigger fingers, odontoid dysplasia or hypoplasia, and severe scoliosis [<xref rid="B118-ijms-19-03063" ref-type="bibr">118</xref>,<xref rid="B119-ijms-19-03063" ref-type="bibr">119</xref>]. Furthermore HSTC does not arrest the progression of many disabling musculoskeletal abnormalities and orthopedic surgery should encourage to enhance quality of life but is also necessary to consider that anesthetic morbidity/mortality is not insignificant in these patients [<xref rid="B119-ijms-19-03063" ref-type="bibr">119</xref>]. Facial deformities, megaloglossia, alteration of cervical and dorsal rachis, airway stenosis represent elements that strongly suggesting a difficult ventilation and/or intubation. Therefore, a preoperative assessment and simulation are needed and a multidisciplinary evaluation should be always performed to evaluate the effective advantages of elective surgical procedures in MPS patients.</p><sec><title>BOX 1</title><p>A 20-year-old girl with MPS IV is followed by our service for chronic cephalgia and low back pain, with a poor response to bethametasone and morphine. At inspection, we observed straight cervical rachis with a severe limitation of the range of motion (ROM); acupressure of dorsal and lumbar spinal apophysis worsened back pain. On the basis of the clinical history and physical examination, a mixed pain, both nociceptive and neuropathic, was diagnosed. Brain and rachis MRI were performed, showing anomalies due to neurological and skeletal involvement by cortical atrophy, cerebral gliosis, diameter reduction of spinal canal at C1&#x02013;D7, diffuse herniated disks with spinal cord compression, and L5-S1 anterior spondylolisthesis. While considering the poor analgesic efficacy of morphine and its side effects, a cannabinoid therapy was successfully started with the association of corticosteroid and opioid treatment at need.</p></sec><sec><title>BOX 2 </title><p>A 15-year-old boy with MPS-3A and severe cognitive impairment was referred to our Pediatric Pain Service for irritability of unknown origin. On examination tetraplegia with arms hypertonia and face grimaces, irregular breath, and moans after left leg mobilization were observed. These elements strongly suggested the presence of nociceptive joint pain. Pain intensity on the r-FLACC scale was 6/10. Acetaminophen was administered (15&#x02009;mg/kg four times daily) with symptom resolution (0/10&#x02009;r-FLACC scale) and a left leg subluxation was detected on X-rays. While considering the high anaesthetic risk, a conservative treatment with a timetable pain therapy was preferred.</p></sec></sec><sec id="sec8-ijms-19-03063"><title>8. Conclusions</title><p>MPS is a chronic disease that involves many organ systems. MPS children often experience chronic pain, but pain is often unsuspected, poorly assessed, and undertreated, and it has a deep negative impact on their quality of life. Effective therapeutic options are still limited and more specific, and targeted molecules are needed. Therefore, it is important to improve the understanding of the physiopathology of pain in order to improve its management and consequently the quality of life of MPS patients and their families.</p></sec></body><back><notes><title>Author Contributions</title><p>F.B., C.D.P. and S.C. study conception and design revised the initial manuscript (Introduction, Discussion, Conclusion) and approved the final manuscript as submitted. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. S.C. drafted the initial manuscript and approved the final manuscript as submitted. M.O. study design, analysis and interpretation of data, revised the initial manuscript and approved the final manuscript as submitted.</p></notes><notes><title>Funding</title><p>This research received no external funding.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><glossary><title>Abbreviations</title><array orientation="portrait"><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1">MPS</td><td valign="middle" align="left" rowspan="1" colspan="1">Mucopolysaccharidoses</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">iNMDs</td><td valign="middle" align="left" rowspan="1" colspan="1">Inherited neurometabolic disorders</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">GAGs</td><td valign="middle" align="left" rowspan="1" colspan="1">Glycosaminoglycans</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">ERT</td><td valign="middle" align="left" rowspan="1" colspan="1">Enzyme replacement therapy</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">HSCT</td><td valign="middle" align="left" rowspan="1" colspan="1">Hematopoietic stem cell therapy</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">ONFH</td><td valign="middle" align="left" rowspan="1" colspan="1">Osteonecrosis of the femoral head</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">NOP</td><td valign="middle" align="left" rowspan="1" colspan="1">Nociceptive pain</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">NR)</td><td valign="middle" align="left" rowspan="1" colspan="1">Neurophatic pain</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">CTS</td><td valign="middle" align="left" rowspan="1" colspan="1">Carpal tunnel syndrome</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">NSAID</td><td valign="middle" align="left" rowspan="1" colspan="1">Nonsteroidal anti-inflammatory drug</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">AAT</td><td valign="middle" align="left" rowspan="1" colspan="1">Animal assisted therapy</td></tr></tbody></array></glossary><ref-list><title>References</title><ref id="B1-ijms-19-03063"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Neufeld</surname><given-names>E.F.</given-names></name><name><surname>Muenzer</surname><given-names>J.</given-names></name></person-group><article-title>The Mucopolysaccharidoses</article-title><source>The Online Metabolic and Molecular Bases of Inherited Disease</source><publisher-name>McGraw-Hill Medical</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2014</year></element-citation></ref><ref id="B2-ijms-19-03063"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cassis</surname><given-names>L.</given-names></name><name><surname>Cort&#x000e8;s-Saladelafont</surname><given-names>E.</given-names></name><name><surname>Molero-Luis</surname><given-names>M.</given-names></name><name><surname>Yubero</surname><given-names>D.</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>M.J.</given-names></name><name><surname>Ormaz&#x000e1;bal</surname><given-names>A.</given-names></name><name><surname>Fons</surname><given-names>C.</given-names></name><name><surname>Jou</surname><given-names>C.</given-names></name><name><surname>Sierra</surname><given-names>C.</given-names></name><name><surname>Castejon Ponce</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Review and evaluation of the methodological quality of the existing guidelines and recommendations for inherited neurometabolic disorders</article-title><source>Orphanet J. Rare Dis.</source><year>2015</year><volume>10</volume><fpage>164</fpage><pub-id pub-id-type="doi">10.1186/s13023-015-0376-9</pub-id><?supplied-pmid 26714856?><pub-id pub-id-type="pmid">26714856</pub-id></element-citation></ref><ref id="B3-ijms-19-03063"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baehner</surname><given-names>F.</given-names></name><name><surname>Schmiedeskamp</surname><given-names>C.</given-names></name><name><surname>Krummenauer</surname><given-names>F.</given-names></name><name><surname>Miebach</surname><given-names>E.</given-names></name><name><surname>Bajbouj</surname><given-names>M.</given-names></name><name><surname>Whybra</surname><given-names>C.</given-names></name><name><surname>Kohlsch&#x000fc;tter</surname><given-names>A.</given-names></name><name><surname>Kampmann</surname><given-names>C.</given-names></name><name><surname>Beck</surname><given-names>M.</given-names></name></person-group><article-title>Cumulative incidence rates of the mucopolysaccharidoses in Germany</article-title><source>J. Inherit. Metab. Dis.</source><year>2005</year><volume>28</volume><fpage>1011</fpage><lpage>1017</lpage><pub-id pub-id-type="doi">10.1007/s10545-005-0112-z</pub-id><?supplied-pmid 16435194?><pub-id pub-id-type="pmid">16435194</pub-id></element-citation></ref><ref id="B4-ijms-19-03063"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>J.</given-names></name><name><surname>Crowhurst</surname><given-names>J.</given-names></name><name><surname>Carey</surname><given-names>B.</given-names></name><name><surname>Greed</surname><given-names>L.</given-names></name></person-group><article-title>Incidence of the mucopolysaccharidoses in Western Australia</article-title><source>Am. J. Med. Genet.</source><year>2003</year><volume>123A</volume><fpage>310</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.20314</pub-id><?supplied-pmid 14608657?><pub-id pub-id-type="pmid">14608657</pub-id></element-citation></ref><ref id="B5-ijms-19-03063"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben Turkia</surname><given-names>H.</given-names></name><name><surname>Tebib</surname><given-names>N.</given-names></name><name><surname>Azzouz</surname><given-names>H.</given-names></name><name><surname>Abdelmoula</surname><given-names>M.S.</given-names></name><name><surname>Ben Chehida</surname><given-names>A.</given-names></name><name><surname>Chemli</surname><given-names>J.</given-names></name><name><surname>Monastiri</surname><given-names>K.</given-names></name><name><surname>Chaabouni</surname><given-names>M.</given-names></name><name><surname>Sanhagi</surname><given-names>H.</given-names></name><name><surname>Zouari</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Incidence of mucopolysaccharidoses in Tunisia</article-title><source>Tunis. Med.</source><year>2009</year><volume>87</volume><fpage>782</fpage><lpage>785</lpage><?supplied-pmid 20209839?><pub-id pub-id-type="pmid">20209839</pub-id></element-citation></ref><ref id="B6-ijms-19-03063"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>H.-Y.</given-names></name><name><surname>Lin</surname><given-names>S.-P.</given-names></name><name><surname>Chuang</surname><given-names>C.-K.</given-names></name><name><surname>Niu</surname><given-names>D.-M.</given-names></name><name><surname>Chen</surname><given-names>M.-R.</given-names></name><name><surname>Tsai</surname><given-names>F.-J.</given-names></name><name><surname>Chao</surname><given-names>M.-C.</given-names></name><name><surname>Chiu</surname><given-names>P.-C.</given-names></name><name><surname>Lin</surname><given-names>S.-J.</given-names></name><name><surname>Tsai</surname><given-names>L.-P.</given-names></name><etal/></person-group><article-title>Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004</article-title><source>Am. J. Med. Genet. Part A</source><year>2009</year><volume>149A</volume><fpage>960</fpage><lpage>964</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.32781</pub-id><?supplied-pmid 19396827?><pub-id pub-id-type="pmid">19396827</pub-id></element-citation></ref><ref id="B7-ijms-19-03063"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malm</surname><given-names>G.</given-names></name><name><surname>Lund</surname><given-names>A.M.</given-names></name><name><surname>M&#x000e5;nsson</surname><given-names>J.-E.</given-names></name><name><surname>Heiberg</surname><given-names>A.</given-names></name></person-group><article-title>Mucopolysaccharidoses in the Scandinavian countries: Incidence and prevalence</article-title><source>Acta Paediatr.</source><year>2008</year><volume>97</volume><fpage>1577</fpage><lpage>1581</lpage><pub-id pub-id-type="doi">10.1111/j.1651-2227.2008.00965.x</pub-id><?supplied-pmid 18681890?><pub-id pub-id-type="pmid">18681890</pub-id></element-citation></ref><ref id="B8-ijms-19-03063"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendriksz</surname><given-names>C.J.</given-names></name><name><surname>Berger</surname><given-names>K.I.</given-names></name><name><surname>Giugliani</surname><given-names>R.</given-names></name><name><surname>Harmatz</surname><given-names>P.</given-names></name><name><surname>Kampmann</surname><given-names>C.</given-names></name><name><surname>Mackenzie</surname><given-names>W.G.</given-names></name><name><surname>Raiman</surname><given-names>J.</given-names></name><name><surname>Villarreal</surname><given-names>M.S.</given-names></name><name><surname>Savarirayan</surname><given-names>R.</given-names></name></person-group><article-title>International guidelines for the management and treatment of Morquio A syndrome</article-title><source>Am. J. Med. Genet. Part A</source><year>2015</year><volume>167</volume><fpage>11</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.36833</pub-id><?supplied-pmid 25346323?><pub-id pub-id-type="pmid">25346323</pub-id></element-citation></ref><ref id="B9-ijms-19-03063"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavery</surname><given-names>C.</given-names></name><name><surname>Hendriksz</surname><given-names>C.</given-names></name></person-group><article-title>Mortality in Patients with Morquio Syndrome A</article-title><source>JIMD Rep.</source><year>2015</year><volume>15</volume><fpage>59</fpage><lpage>66</lpage><?supplied-pmid 24718838?><pub-id pub-id-type="pmid">24718838</pub-id></element-citation></ref><ref id="B10-ijms-19-03063"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>T.C.</given-names></name><name><surname>Harvey</surname><given-names>K.</given-names></name><name><surname>Beck</surname><given-names>M.</given-names></name><name><surname>Burin</surname><given-names>M.G.</given-names></name><name><surname>Chien</surname><given-names>Y.-H.</given-names></name><name><surname>Church</surname><given-names>H.J.</given-names></name><name><surname>D&#x02019;Almeida</surname><given-names>V.</given-names></name><name><surname>van Diggelen</surname><given-names>O.P.</given-names></name><name><surname>Fietz</surname><given-names>M.</given-names></name><name><surname>Giugliani</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Diagnosing mucopolysaccharidosis IVA</article-title><source>J. Inherit. Metab. Dis.</source><year>2013</year><volume>36</volume><fpage>293</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1007/s10545-013-9587-1</pub-id><?supplied-pmid 23371450?><pub-id pub-id-type="pmid">23371450</pub-id></element-citation></ref><ref id="B11-ijms-19-03063"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brands</surname><given-names>M.M.G.</given-names></name><name><surname>G&#x000fc;ng&#x000f6;r</surname><given-names>D.</given-names></name><name><surname>van den Hout</surname><given-names>J.M.P.</given-names></name><name><surname>Karstens</surname><given-names>F.P.J.</given-names></name><name><surname>Oussoren</surname><given-names>E.</given-names></name><name><surname>Plug</surname><given-names>I.</given-names></name><name><surname>Boelens</surname><given-names>J.J.</given-names></name><name><surname>van Hasselt</surname><given-names>P.M.</given-names></name><name><surname>Hollak</surname><given-names>C.E.M.</given-names></name><name><surname>Mulder</surname><given-names>M.F.</given-names></name><etal/></person-group><article-title>Pain: A prevalent feature in patients with mucopolysaccharidosis. Results of a cross-sectional national survey</article-title><source>J. Inherit. Metab. Dis.</source><year>2015</year><volume>38</volume><fpage>323</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1007/s10545-014-9737-0</pub-id><?supplied-pmid 25048386?><pub-id pub-id-type="pmid">25048386</pub-id></element-citation></ref><ref id="B12-ijms-19-03063"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendriksz</surname><given-names>C.J.</given-names></name><name><surname>Burton</surname><given-names>B.</given-names></name><name><surname>Fleming</surname><given-names>T.R.</given-names></name><name><surname>Harmatz</surname><given-names>P.</given-names></name><name><surname>Hughes</surname><given-names>D.</given-names></name><name><surname>Jones</surname><given-names>S.A.</given-names></name><name><surname>Lin</surname><given-names>S.P.</given-names></name><name><surname>Mengel</surname><given-names>E.</given-names></name><name><surname>Scarpa</surname><given-names>M.</given-names></name><name><surname>Valayannopoulos</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): A phase 3 randomised placebo-controlled study</article-title><source>J. Inherit. Metab. Dis.</source><year>2014</year><volume>37</volume><fpage>979</fpage><lpage>990</lpage><pub-id pub-id-type="doi">10.1007/s10545-014-9715-6</pub-id><?supplied-pmid 24810369?><pub-id pub-id-type="pmid">24810369</pub-id></element-citation></ref><ref id="B13-ijms-19-03063"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harmatz</surname><given-names>P.</given-names></name><name><surname>Hendriksz</surname><given-names>C.J.</given-names></name><name><surname>Lampe</surname><given-names>C.</given-names></name><name><surname>McGill</surname><given-names>J.J.</given-names></name><name><surname>Parini</surname><given-names>R.</given-names></name><name><surname>Le&#x000e3;o-Teles</surname><given-names>E.</given-names></name><name><surname>Valayannopoulos</surname><given-names>V.</given-names></name><name><surname>Cole</surname><given-names>T.J.</given-names></name><name><surname>Matousek</surname><given-names>R.</given-names></name><name><surname>Graham</surname><given-names>S.</given-names></name><etal/></person-group><article-title>MPS VI Study Group. The effect of galsulfase enzyme replacement therapy on the growth of patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)</article-title><source>Mol. Genet. Metab.</source><year>2017</year><volume>122</volume><fpage>107</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/j.ymgme.2017.03.008</pub-id><?supplied-pmid 28457718?><pub-id pub-id-type="pmid">28457718</pub-id></element-citation></ref><ref id="B14-ijms-19-03063"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Ru</surname><given-names>M.H.</given-names></name><name><surname>Boelens</surname><given-names>J.J.</given-names></name><name><surname>Das</surname><given-names>A.M.</given-names></name><name><surname>Jones</surname><given-names>S.A.</given-names></name><name><surname>van der Lee</surname><given-names>J.H.</given-names></name><name><surname>Mahlaoui</surname><given-names>N.</given-names></name><name><surname>Mengel</surname><given-names>E.</given-names></name><name><surname>Offringa</surname><given-names>M.</given-names></name><name><surname>O'Meara</surname><given-names>A.</given-names></name><name><surname>Parini</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Enzyme Replacement Therapy and/or Hematopoietic Stem Cell Transplantation at diagnosis in patients with Mucopolysaccharidosis type I: Results of a European consensus procedure</article-title><source>Orphanet J. Rare Dis.</source><year>2011</year><volume>6</volume><fpage>55</fpage><pub-id pub-id-type="doi">10.1186/1750-1172-6-55</pub-id><?supplied-pmid 21831279?><pub-id pub-id-type="pmid">21831279</pub-id></element-citation></ref><ref id="B15-ijms-19-03063"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harmatz</surname><given-names>P.</given-names></name><name><surname>Ketteridge</surname><given-names>D.</given-names></name><name><surname>Giugliani</surname><given-names>R.</given-names></name><name><surname>Guffon</surname><given-names>N.</given-names></name><name><surname>Teles</surname><given-names>E.L.</given-names></name><name><surname>Miranda</surname><given-names>M.C.S.</given-names></name><name><surname>Yu</surname><given-names>Z.F.</given-names></name><name><surname>Swiedler</surname><given-names>S.J.</given-names></name></person-group><article-title>Direct Comparison of Measures of Endurance, Mobility, and Joint Function During Enzyme-Replacement Therapy of Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome): Results After 48 Weeks in a Phase 2 Open-Label Clinical Study of Recombinant Human N-acetylgalactosamine 4-sulfatase</article-title><source>Pediatrics</source><year>2005</year><volume>115</volume><fpage>e681</fpage><lpage>e689</lpage><?supplied-pmid 15930196?><pub-id pub-id-type="pmid">15930196</pub-id></element-citation></ref><ref id="B16-ijms-19-03063"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>L.A.</given-names></name><name><surname>Wraith</surname><given-names>J.E.</given-names></name><name><surname>Beck</surname><given-names>M.</given-names></name><name><surname>Kolodny</surname><given-names>E.H.</given-names></name><name><surname>Pastores</surname><given-names>G.M.</given-names></name><name><surname>Muenzer</surname><given-names>J.</given-names></name><name><surname>Rapoport</surname><given-names>D.M.</given-names></name><name><surname>Berger</surname><given-names>K.I.</given-names></name><name><surname>Sidman</surname><given-names>M.</given-names></name><name><surname>Kakkis</surname><given-names>E.D.</given-names></name><etal/></person-group><article-title>Long-term Efficacy and Safety of Laronidase in the Treatment of Mucopolysaccharidosis I</article-title><source>Pediatrics</source><year>2009</year><volume>123</volume><fpage>229</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1542/peds.2007-3847</pub-id><?supplied-pmid 19117887?><pub-id pub-id-type="pmid">19117887</pub-id></element-citation></ref><ref id="B17-ijms-19-03063"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogler</surname><given-names>C.</given-names></name><name><surname>Levy</surname><given-names>B.</given-names></name><name><surname>Galvin</surname><given-names>N.</given-names></name><name><surname>Lessard</surname><given-names>M.</given-names></name><name><surname>Soper</surname><given-names>B.</given-names></name><name><surname>Barker</surname><given-names>J.</given-names></name></person-group><article-title>Early Onset of Lysosomal Storage Disease in a Murine Model of Mucopolysaccharidosis Type VII: Undegraded Substrate Accumulates in Many Tissues in the Fetus and Very Young MPS VII Mouse</article-title><source>Pediatr. Dev. Pathol.</source><year>2005</year><volume>8</volume><fpage>453</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1007/s10024-005-0025-8</pub-id><?supplied-pmid 16222480?><pub-id pub-id-type="pmid">16222480</pub-id></element-citation></ref><ref id="B18-ijms-19-03063"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.H.</given-names></name><name><surname>Yu</surname><given-names>W.H.</given-names></name><name><surname>Rozengurt</surname><given-names>N.</given-names></name><name><surname>Zhao</surname><given-names>H.Z.</given-names></name><name><surname>Lyons</surname><given-names>K.M.</given-names></name><name><surname>Anagnostaras</surname><given-names>S.</given-names></name><name><surname>Fanselow</surname><given-names>M.S.</given-names></name><name><surname>Suzuki</surname><given-names>K.</given-names></name><name><surname>Vanier</surname><given-names>M.T.</given-names></name><name><surname>Neufeld</surname><given-names>E.F.</given-names></name><etal/></person-group><article-title>Mouse model of Sanfilippo syndrome type B produced by targeted disruption of the gene encoding alpha-N-acetylglucosaminidase</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1999</year><volume>96</volume><fpage>14505</fpage><lpage>14510</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.25.14505</pub-id><?supplied-pmid 10588735?><pub-id pub-id-type="pmid">10588735</pub-id></element-citation></ref><ref id="B19-ijms-19-03063"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhaumik</surname><given-names>M.</given-names></name><name><surname>Muller</surname><given-names>V.J.</given-names></name><name><surname>Rozaklis</surname><given-names>T.</given-names></name><name><surname>Johnson</surname><given-names>L.</given-names></name><name><surname>Dobrenis</surname><given-names>K.</given-names></name><name><surname>Bhattacharyya</surname><given-names>R.</given-names></name><name><surname>Wurzelmann</surname><given-names>S.</given-names></name><name><surname>Finamore</surname><given-names>P.</given-names></name><name><surname>Hopwood</surname><given-names>J.J.</given-names></name><name><surname>Walkley</surname><given-names>S.U.</given-names></name><etal/></person-group><article-title>A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome)</article-title><source>Glycobiology</source><year>1999</year><volume>9</volume><fpage>1389</fpage><lpage>1396</lpage><pub-id pub-id-type="doi">10.1093/glycob/9.12.1389</pub-id><?supplied-pmid 10561464?><pub-id pub-id-type="pmid">10561464</pub-id></element-citation></ref><ref id="B20-ijms-19-03063"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>C.</given-names></name><name><surname>Hendson</surname><given-names>G.</given-names></name><name><surname>Jevon</surname><given-names>G.</given-names></name><name><surname>Matlock</surname><given-names>T.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Aklujkar</surname><given-names>M.</given-names></name><name><surname>Ng</surname><given-names>K.Y.</given-names></name><name><surname>Clarke</surname><given-names>L.A.</given-names></name></person-group><article-title>Murine MPS I: Insights into the pathogenesis of Hurler syndrome</article-title><source>Clin. Genet.</source><year>1998</year><volume>53</volume><fpage>349</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1111/j.1399-0004.1998.tb02745.x</pub-id><?supplied-pmid 9660052?><pub-id pub-id-type="pmid">9660052</pub-id></element-citation></ref><ref id="B21-ijms-19-03063"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>M.Z.</given-names></name><name><surname>Alroy</surname><given-names>J.</given-names></name><name><surname>Rutledge</surname><given-names>J.C.</given-names></name><name><surname>Taylor</surname><given-names>J.W.</given-names></name><name><surname>Alvord</surname><given-names>E.C.</given-names></name><name><surname>Toone</surname><given-names>J.</given-names></name><name><surname>Applegarth</surname><given-names>D.</given-names></name><name><surname>Hopwood</surname><given-names>J.J.</given-names></name><name><surname>Skutelsky</surname><given-names>E.</given-names></name><name><surname>Ianelli</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Human mucopolysaccharidosis IIID: Clinical, biochemical, morphological and immunohistochemical characteristics</article-title><source>J. Neuropathol. Exp. Neurol.</source><year>1997</year><volume>56</volume><fpage>1158</fpage><lpage>1167</lpage><pub-id pub-id-type="doi">10.1097/00005072-199710000-00010</pub-id><?supplied-pmid 9329460?><pub-id pub-id-type="pmid">9329460</pub-id></element-citation></ref><ref id="B22-ijms-19-03063"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Constantopoulos</surname><given-names>G.</given-names></name><name><surname>Dekaban</surname><given-names>A.S.</given-names></name></person-group><article-title>Neurochemistry of the mucopolysaccharidoses: Brain lipids and lysosomal enzymes in patients with four types of mucopolysaccharidosis and in normal controls</article-title><source>J. Neurochem.</source><year>1978</year><volume>30</volume><fpage>965</fpage><lpage>973</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.1978.tb12388.x</pub-id><?supplied-pmid 96217?><pub-id pub-id-type="pmid">96217</pub-id></element-citation></ref><ref id="B23-ijms-19-03063"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walkley</surname><given-names>S.U.</given-names></name></person-group><article-title>Secondary accumulation of gangliosides in lysosomal storage disorders</article-title><source>Semin. Cell Dev. Biol.</source><year>2004</year><volume>15</volume><fpage>433</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2004.03.002</pub-id><?supplied-pmid 15207833?><pub-id pub-id-type="pmid">15207833</pub-id></element-citation></ref><ref id="B24-ijms-19-03063"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walkley</surname><given-names>S.U.</given-names></name><name><surname>Thrall</surname><given-names>M.A.</given-names></name><name><surname>Haskins</surname><given-names>M.E.</given-names></name><name><surname>Mitchell</surname><given-names>T.W.</given-names></name><name><surname>Wenger</surname><given-names>D.A.</given-names></name><name><surname>Brown</surname><given-names>D.E.</given-names></name><name><surname>Dial</surname><given-names>S.</given-names></name><name><surname>Seim</surname><given-names>H.</given-names></name></person-group><article-title>Abnormal neuronal metabolism and storage in mucopolysaccharidosis type VI (Maroteaux-Lamy) disease</article-title><source>Neuropathol. Appl. Neurobiol.</source><year>2005</year><volume>31</volume><fpage>536</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2990.2005.00675.x</pub-id><?supplied-pmid 16150124?><pub-id pub-id-type="pmid">16150124</pub-id></element-citation></ref><ref id="B25-ijms-19-03063"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>M.Z.</given-names></name><name><surname>Alroy</surname><given-names>J.</given-names></name><name><surname>Boyer</surname><given-names>P.J.</given-names></name><name><surname>Cavanagh</surname><given-names>K.T.</given-names></name><name><surname>Johnson</surname><given-names>K.</given-names></name><name><surname>Gage</surname><given-names>D.</given-names></name><name><surname>Vorro</surname><given-names>D.</given-names></name><name><surname>Render</surname><given-names>J.A.</given-names></name><name><surname>Common</surname><given-names>R.S.</given-names></name><name><surname>Leedle</surname><given-names>R.A.</given-names></name><etal/></person-group><article-title>Caprine mucopolysaccharidosis-IIID: Clinical, biochemical, morphological and immunohistochemical characteristics</article-title><source>J. Neuropathol. Exp. Neurol.</source><year>1998</year><volume>57</volume><fpage>148</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1097/00005072-199802000-00006</pub-id><?supplied-pmid 9600207?><pub-id pub-id-type="pmid">9600207</pub-id></element-citation></ref><ref id="B26-ijms-19-03063"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGlynn</surname><given-names>R.</given-names></name><name><surname>Dobrenis</surname><given-names>K.</given-names></name><name><surname>Walkley</surname><given-names>S.U.</given-names></name></person-group><article-title>Differential subcellular localization of cholesterol, gangliosides, and glycosaminoglycans in murine models of mucopolysaccharide storage disorders</article-title><source>J. Comp. Neurol.</source><year>2004</year><volume>480</volume><fpage>415</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1002/cne.20355</pub-id><?supplied-pmid 15558784?><pub-id pub-id-type="pmid">15558784</pub-id></element-citation></ref><ref id="B27-ijms-19-03063"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walkley</surname><given-names>S.U.</given-names></name><name><surname>Suzuki</surname><given-names>K.</given-names></name></person-group><article-title>Consequences of NPC1 and NPC2 loss of function in mammalian neurons</article-title><source>Biochim. Biophys. Acta Mol. Cell Biol. Lipids</source><year>2004</year><volume>1685</volume><fpage>48</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.bbalip.2004.08.011</pub-id><?supplied-pmid 15465426?><pub-id pub-id-type="pmid">15465426</pub-id></element-citation></ref><ref id="B28-ijms-19-03063"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pagano</surname><given-names>R.E.</given-names></name><name><surname>Puri</surname><given-names>V.</given-names></name><name><surname>Dominguez</surname><given-names>M.</given-names></name><name><surname>Marks</surname><given-names>D.L.</given-names></name></person-group><article-title>Membrane traffic in sphingolipid storage diseases</article-title><source>Traffic</source><year>2000</year><volume>1</volume><fpage>807</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1034/j.1600-0854.2000.011101.x</pub-id><?supplied-pmid 11208071?><pub-id pub-id-type="pmid">11208071</pub-id></element-citation></ref><ref id="B29-ijms-19-03063"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeyakumar</surname><given-names>M.</given-names></name><name><surname>Thomas</surname><given-names>R.</given-names></name><name><surname>Elliot-Smith</surname><given-names>E.</given-names></name><name><surname>Smith</surname><given-names>D.A.</given-names></name><name><surname>van der Spoel</surname><given-names>A.C.</given-names></name><name><surname>d&#x02019;Azzo</surname><given-names>A.</given-names></name><name><surname>Hugh Perry</surname><given-names>V.</given-names></name><name><surname>Butters</surname><given-names>T.D.</given-names></name><name><surname>Dwek</surname><given-names>R.A.</given-names></name><name><surname>Platt</surname><given-names>F.M.</given-names></name><etal/></person-group><article-title>Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis</article-title><source>Brain</source><year>2003</year><volume>126</volume><issue-part>Pt 4</issue-part><fpage>974</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.1093/brain/awg089</pub-id><?supplied-pmid 12615653?><pub-id pub-id-type="pmid">12615653</pub-id></element-citation></ref><ref id="B30-ijms-19-03063"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohmi</surname><given-names>K.</given-names></name><name><surname>Greenberg</surname><given-names>D.S.</given-names></name><name><surname>Rajavel</surname><given-names>K.S.</given-names></name><name><surname>Ryazantsev</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>H.H.</given-names></name><name><surname>Neufeld</surname><given-names>E.F.</given-names></name></person-group><article-title>Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2003</year><volume>100</volume><fpage>1902</fpage><lpage>1907</lpage><pub-id pub-id-type="doi">10.1073/pnas.252784899</pub-id><?supplied-pmid 12576554?><pub-id pub-id-type="pmid">12576554</pub-id></element-citation></ref><ref id="B31-ijms-19-03063"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simonaro</surname><given-names>C.M.</given-names></name><name><surname>Ge</surname><given-names>Y.</given-names></name><name><surname>Eliyahu</surname><given-names>E.</given-names></name><name><surname>He</surname><given-names>X.</given-names></name><name><surname>Jepsen</surname><given-names>K.J.</given-names></name><name><surname>Schuchman</surname><given-names>E.H.</given-names></name></person-group><article-title>Involvement of the Toll-like receptor 4 pathway and use of TNF antagonists for treatment of the mucopolysaccharidoses</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>222</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1073/pnas.0912937107</pub-id><?supplied-pmid 20018674?><pub-id pub-id-type="pmid">20018674</pub-id></element-citation></ref><ref id="B32-ijms-19-03063"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simonaro</surname><given-names>C.M.</given-names></name><name><surname>D&#x02019;Angelo</surname><given-names>M.</given-names></name><name><surname>He</surname><given-names>X.</given-names></name><name><surname>Eliyahu</surname><given-names>E.</given-names></name><name><surname>Shtraizent</surname><given-names>N.</given-names></name><name><surname>Haskins</surname><given-names>M.E.</given-names></name><name><surname>Schuchman</surname><given-names>E.H.</given-names></name></person-group><article-title>Mechanism of glycosaminoglycan-mediated bone and joint disease: Implications for the mucopolysaccharidoses and other connective tissue diseases</article-title><source>Am. J. Pathol.</source><year>2008</year><volume>172</volume><fpage>112</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2008.070564</pub-id><?supplied-pmid 18079441?><pub-id pub-id-type="pmid">18079441</pub-id></element-citation></ref><ref id="B33-ijms-19-03063"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>S.U.</given-names></name><name><surname>Hashamiyan</surname><given-names>S.</given-names></name><name><surname>Clarke</surname><given-names>L.</given-names></name><name><surname>Saftig</surname><given-names>P.</given-names></name><name><surname>Mort</surname><given-names>J.</given-names></name><name><surname>Dejica</surname><given-names>V.M.</given-names></name><name><surname>Br&#x000f6;mme</surname><given-names>D.</given-names></name></person-group><article-title>Glycosaminoglycan-Mediated Loss of Cathepsin K Collagenolytic Activity in MPS I Contributes to Osteoclast and Growth Plate Abnormalities</article-title><source>Am. J. Pathol.</source><year>2009</year><volume>175</volume><fpage>2053</fpage><lpage>2062</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2009.090211</pub-id><?supplied-pmid 19834056?><pub-id pub-id-type="pmid">19834056</pub-id></element-citation></ref><ref id="B34-ijms-19-03063"><label>34.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Zeltzer</surname><given-names>L.K.</given-names></name><name><surname>Krell</surname><given-names>H.</given-names></name></person-group><article-title>Pediatric Pain Management</article-title><source>Nelson Textbook of Pediatrics</source><edition>19th ed.</edition><person-group person-group-type="editor"><name><surname>Kliegman</surname><given-names>R.M.</given-names></name><name><surname>Stanton</surname><given-names>B.F.</given-names></name><name><surname>St. Geme</surname><given-names>J.W.</given-names></name><name><surname>Schor</surname><given-names>N.F.</given-names></name></person-group><publisher-name>Elsevier Saunders</publisher-name><publisher-loc>Philadelphia, PA, USA</publisher-loc><year>2011</year><fpage>36</fpage><lpage>375</lpage></element-citation></ref><ref id="B35-ijms-19-03063"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lampe</surname><given-names>C.</given-names></name><name><surname>Bellettato</surname><given-names>C.M.</given-names></name><name><surname>Karabul</surname><given-names>N.</given-names></name><name><surname>Scarpa</surname><given-names>M.</given-names></name></person-group><article-title>Mucopolysaccharidoses and Other Lysosomal Storage Diseases</article-title><source>Rheum. Dis. Clin. N. Am.</source><year>2013</year><volume>39</volume><fpage>431</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1016/j.rdc.2013.03.004</pub-id><?supplied-pmid 23597973?><pub-id pub-id-type="pmid">23597973</pub-id></element-citation></ref><ref id="B36-ijms-19-03063"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aldenhoven</surname><given-names>M.</given-names></name><name><surname>Sakkers</surname><given-names>R.J.B.</given-names></name><name><surname>Boelens</surname><given-names>J.</given-names></name><name><surname>de Koning</surname><given-names>T.J.</given-names></name><name><surname>Wulffraat</surname><given-names>N.M.</given-names></name></person-group><article-title>Musculoskeletal manifestations of lysosomal storage disorders</article-title><source>Ann. Rheum. Dis.</source><year>2009</year><volume>68</volume><fpage>1659</fpage><lpage>1665</lpage><pub-id pub-id-type="doi">10.1136/ard.2008.095315</pub-id><?supplied-pmid 19822711?><pub-id pub-id-type="pmid">19822711</pub-id></element-citation></ref><ref id="B37-ijms-19-03063"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haddad</surname><given-names>F.S.</given-names></name><name><surname>Hill</surname><given-names>R.A.</given-names></name><name><surname>Jones</surname><given-names>D.H.</given-names></name></person-group><article-title>Triggering in the mucopolysaccharidoses</article-title><source>J. Pediatr. Orthop. B</source><year>1998</year><volume>7</volume><fpage>138</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1097/01202412-199804000-00009</pub-id><?supplied-pmid 9597590?><pub-id pub-id-type="pmid">9597590</pub-id></element-citation></ref><ref id="B38-ijms-19-03063"><label>38.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Orlandini</surname><given-names>G.</given-names></name></person-group><source>La Semeiotica Del Dolore</source><person-group person-group-type="editor"><name><surname>Delfino</surname><given-names>A.</given-names></name></person-group><publisher-name>Weidmuller</publisher-name><publisher-loc>Rome, Italy</publisher-loc><month>11</month><year>2013</year><isbn>9788872874929</isbn></element-citation></ref><ref id="B39-ijms-19-03063"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witt</surname><given-names>K.L.</given-names></name><name><surname>Vilensky</surname><given-names>J.A.</given-names></name></person-group><article-title>The anatomy of osteoarthritic joint pain</article-title><source>Clin. Anat.</source><year>2014</year><volume>27</volume><fpage>451</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1002/ca.22120</pub-id><?supplied-pmid 22730047?><pub-id pub-id-type="pmid">22730047</pub-id></element-citation></ref><ref id="B40-ijms-19-03063"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vlodaver</surname><given-names>Z.</given-names></name><name><surname>Neufeld</surname><given-names>H.N.</given-names></name><name><surname>Edwards</surname><given-names>J.E.</given-names></name></person-group><article-title>Pathology of Angina Pectoris</article-title><source>Circulation</source><year>1972</year><volume>46</volume><fpage>1048</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.46.6.1048</pub-id><?supplied-pmid 4404549?><pub-id pub-id-type="pmid">4404549</pub-id></element-citation></ref><ref id="B41-ijms-19-03063"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindsay</surname><given-names>S.</given-names></name></person-group><article-title>The cardiovascular system in gargoylism</article-title><source>Br. Heart J.</source><year>1950</year><volume>12</volume><fpage>17</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1136/hrt.12.1.17</pub-id><?supplied-pmid 15409364?><pub-id pub-id-type="pmid">15409364</pub-id></element-citation></ref><ref id="B42-ijms-19-03063"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vijay</surname><given-names>S.</given-names></name><name><surname>Wraith</surname><given-names>J.</given-names></name></person-group><article-title>Clinical presentation and follow-up of patients with the attenuated phenotype of mucopolysaccharidosis type I</article-title><source>Acta Paediatr.</source><year>2005</year><volume>94</volume><fpage>872</fpage><lpage>877</lpage><pub-id pub-id-type="doi">10.1080/08035250510031584</pub-id><?supplied-pmid 16188808?><pub-id pub-id-type="pmid">16188808</pub-id></element-citation></ref><ref id="B43-ijms-19-03063"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daousi</surname><given-names>C.</given-names></name><name><surname>MacFarlane</surname><given-names>I.A.</given-names></name><name><surname>Woodward</surname><given-names>A.</given-names></name><name><surname>Nurmikko</surname><given-names>T.J.</given-names></name><name><surname>Bundred</surname><given-names>P.E.</given-names></name><name><surname>Benbow</surname><given-names>S.J.</given-names></name></person-group><article-title>Chronic painful peripheral neuropathy in an urban community: A controlled comparison of people with and without diabetes</article-title><source>Diabet. Med.</source><year>2004</year><volume>21</volume><fpage>976</fpage><lpage>982</lpage><pub-id pub-id-type="doi">10.1111/j.1464-5491.2004.01271.x</pub-id><?supplied-pmid 15317601?><pub-id pub-id-type="pmid">15317601</pub-id></element-citation></ref><ref id="B44-ijms-19-03063"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddall</surname><given-names>P.J.</given-names></name><name><surname>McClelland</surname><given-names>J.M.</given-names></name><name><surname>Rutkowski</surname><given-names>S.B.</given-names></name><name><surname>Cousins</surname><given-names>M.J.</given-names></name></person-group><article-title>A longitudinal study of the prevalence and characteristics of pain in the first 5 years following spinal cord injury</article-title><source>Pain</source><year>2003</year><volume>103</volume><fpage>249</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1016/S0304-3959(02)00452-9</pub-id><pub-id pub-id-type="pmid">12791431</pub-id></element-citation></ref><ref id="B45-ijms-19-03063"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonohata</surname><given-names>M.</given-names></name><name><surname>Tsuruta</surname><given-names>T.</given-names></name><name><surname>Mine</surname><given-names>H.</given-names></name><name><surname>Asami</surname><given-names>A.</given-names></name><name><surname>Ishii</surname><given-names>H.</given-names></name><name><surname>Tsunoda</surname><given-names>K.</given-names></name><name><surname>Morimoto</surname><given-names>T.</given-names></name><name><surname>Mawatari</surname><given-names>M.</given-names></name></person-group><article-title>Clinical characteristics of neuropathic pain in patients with carpal tunnel syndrome</article-title><source>Hand Surg.</source><year>2014</year><volume>19</volume><fpage>43</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1142/S0218810414500087</pub-id><?supplied-pmid 24641740?><pub-id pub-id-type="pmid">24641740</pub-id></element-citation></ref><ref id="B46-ijms-19-03063"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bland</surname><given-names>J.D.P.</given-names></name></person-group><article-title>Carpal tunnel syndrome</article-title><source>BMJ</source><year>2007</year><volume>335</volume><fpage>343</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1136/bmj.39282.623553.AD</pub-id><?supplied-pmid 17703044?><pub-id pub-id-type="pmid">17703044</pub-id></element-citation></ref><ref id="B47-ijms-19-03063"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Qattan</surname><given-names>M.M.</given-names></name><name><surname>Thomson</surname><given-names>H.G.</given-names></name><name><surname>Clarke</surname><given-names>H.M.</given-names></name></person-group><article-title>Carpal tunnel syndrome in children and adolescents with no history of trauma</article-title><source>J. Hand Surg Br.</source><year>1996</year><volume>21</volume><fpage>108</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/S0266-7681(96)80023-4</pub-id><pub-id pub-id-type="pmid">8676014</pub-id></element-citation></ref><ref id="B48-ijms-19-03063"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomatsu</surname><given-names>S.</given-names></name><name><surname>Yasuda</surname><given-names>E.</given-names></name><name><surname>Patel</surname><given-names>P.</given-names></name><name><surname>Ruhnke</surname><given-names>K.</given-names></name><name><surname>Shimada</surname><given-names>T.</given-names></name><name><surname>Mackenzie</surname><given-names>W.G.</given-names></name><name><surname>Mason</surname><given-names>R.</given-names></name><name><surname>Thacker</surname><given-names>M.M.</given-names></name><name><surname>Theroux</surname><given-names>M.</given-names></name><name><surname>Monta&#x000f1;o</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Morquio A syndrome: Diagnosis and current and future therapies</article-title><source>Pediatr. Endocrinol. Rev.</source><year>2014</year><volume>12</volume><issue>Suppl. 1</issue><fpage>141</fpage><lpage>151</lpage><?supplied-pmid 25345096?><pub-id pub-id-type="pmid">25345096</pub-id></element-citation></ref><ref id="B49-ijms-19-03063"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finnerup</surname><given-names>N.B.</given-names></name></person-group><article-title>Pain in patients with spinal cord injury</article-title><source>Pain</source><year>2013</year><volume>154</volume><issue>Suppl. 1</issue><fpage>S71</fpage><lpage>S76</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2012.12.007</pub-id><pub-id pub-id-type="pmid">23375163</pub-id></element-citation></ref><ref id="B50-ijms-19-03063"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forner</surname><given-names>S.</given-names></name><name><surname>Martini</surname><given-names>A.C.</given-names></name><name><surname>de Andrade</surname><given-names>E.L.</given-names></name><name><surname>Rae</surname><given-names>G.A.</given-names></name></person-group><article-title>Neuropathic pain induced by spinal cord injury: Role of endothelin ETA and ETB receptors</article-title><source>Neurosci. Lett.</source><year>2016</year><volume>617</volume><fpage>14</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2016.02.005</pub-id><?supplied-pmid 26861196?><pub-id pub-id-type="pmid">26861196</pub-id></element-citation></ref><ref id="B51-ijms-19-03063"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>C.M.</given-names></name><name><surname>Rogers</surname><given-names>S.D.</given-names></name><name><surname>Pomonis</surname><given-names>J.D.</given-names></name><name><surname>Egnaczyk</surname><given-names>G.F.</given-names></name><name><surname>Keyser</surname><given-names>C.P.</given-names></name><name><surname>Schmidt</surname><given-names>J.A.</given-names></name><name><surname>Ghilardi</surname><given-names>J.R.</given-names></name><name><surname>Maggio</surname><given-names>J.E.</given-names></name><name><surname>Mantyh</surname><given-names>P.W.</given-names></name></person-group><article-title>Endothelin receptor expression in the normal and injured spinal cord: Potential involvement in injury-induced ischemia and gliosis</article-title><source>Exp. Neurol.</source><year>2003</year><volume>180</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/S0014-4886(02)00023-7</pub-id><pub-id pub-id-type="pmid">12668144</pub-id></element-citation></ref><ref id="B52-ijms-19-03063"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>S.P.</given-names></name><name><surname>Mao</surname><given-names>J.</given-names></name></person-group><article-title>Neuropathic pain: Mechanisms and their clinical implications</article-title><source>BMJ</source><year>2014</year><volume>348</volume><fpage>f7656</fpage><pub-id pub-id-type="doi">10.1136/bmj.f7656</pub-id><?supplied-pmid 24500412?><pub-id pub-id-type="pmid">24500412</pub-id></element-citation></ref><ref id="B53-ijms-19-03063"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perquin</surname><given-names>C.W.</given-names></name><name><surname>Hazebroek-Kampschreur</surname><given-names>A.A.</given-names></name><name><surname>Hunfeld</surname><given-names>J.A.</given-names></name><name><surname>Bohnen</surname><given-names>A.M.</given-names></name><name><surname>van Suijlekom-Smit</surname><given-names>L.W.</given-names></name><name><surname>Passchier</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Pain in children and adolescents: A common experience</article-title><source>Pain</source><year>2000</year><volume>87</volume><fpage>51</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/S0304-3959(00)00269-4</pub-id><pub-id pub-id-type="pmid">10863045</pub-id></element-citation></ref><ref id="B54-ijms-19-03063"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuen</surname><given-names>A.</given-names></name><name><surname>Dowling</surname><given-names>G.</given-names></name><name><surname>Johnstone</surname><given-names>B.</given-names></name><name><surname>Kornberg</surname><given-names>A.</given-names></name><name><surname>Coombs</surname><given-names>C.</given-names></name></person-group><article-title>Carpal Tunnel Syndrome in Children with Mucopolysaccaridoses</article-title><source>J. Child Neurol.</source><year>2007</year><volume>22</volume><fpage>260</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1177/0883073807300528</pub-id><?supplied-pmid 17621494?><pub-id pub-id-type="pmid">17621494</pub-id></element-citation></ref><ref id="B55-ijms-19-03063"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>K.K.</given-names></name><name><surname>Sousa</surname><given-names>T.</given-names></name></person-group><article-title>Mucopolysaccharide Disorders in Orthopaedic Surgery</article-title><source>J. Am. Acad. Orthop. Surg.</source><year>2013</year><volume>21</volume><fpage>12</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.5435/JAAOS-21-01-12</pub-id><?supplied-pmid 23281467?><pub-id pub-id-type="pmid">23281467</pub-id></element-citation></ref><ref id="B56-ijms-19-03063"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>L.A.</given-names></name></person-group><article-title>Pathogenesis of skeletal and connective tissue involvement in the mucopolysaccharidoses: Glycosaminoglycan storage is merely the instigator</article-title><source>Rheumatology</source><year>2011</year><volume>50</volume><issue>Suppl. 5</issue><fpage>v13</fpage><lpage>v18</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/ker395</pub-id><?supplied-pmid 22210665?><pub-id pub-id-type="pmid">22210665</pub-id></element-citation></ref><ref id="B57-ijms-19-03063"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendriksz</surname><given-names>C.J.</given-names></name><name><surname>Lavery</surname><given-names>C.</given-names></name><name><surname>Coker</surname><given-names>M.</given-names></name><name><surname>Ucar</surname><given-names>S.K.</given-names></name><name><surname>Jain</surname><given-names>M.</given-names></name><name><surname>Bell</surname><given-names>L.</given-names></name><name><surname>Lampe</surname><given-names>C.</given-names></name></person-group><article-title>Burden of disease in patients with Morquio A syndrome: Results from an international patient-reported outcomes survey</article-title><source>Orphanet J. Rare Dis.</source><year>2014</year><volume>9</volume><fpage>32</fpage><pub-id pub-id-type="doi">10.1186/1750-1172-9-32</pub-id><?supplied-pmid 24602160?><pub-id pub-id-type="pmid">24602160</pub-id></element-citation></ref><ref id="B58-ijms-19-03063"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burton</surname><given-names>B.K.</given-names></name><name><surname>Berger</surname><given-names>K.I.</given-names></name><name><surname>Lewis</surname><given-names>G.D.</given-names></name><name><surname>Tarnopolsky</surname><given-names>M.</given-names></name><name><surname>Treadwell</surname><given-names>M.</given-names></name><name><surname>Mitchell</surname><given-names>J.J.</given-names></name><name><surname>Muschol</surname><given-names>N.</given-names></name><name><surname>Jones</surname><given-names>S.A.</given-names></name><name><surname>Reid Sutton</surname><given-names>V.</given-names></name><name><surname>Pastores</surname><given-names>G.M.</given-names></name><etal/></person-group><article-title>Safety and physiological effects of two different doses of elosulfase alfa in patients with morquio a syndrome: A randomized, double-blind, pilot study</article-title><source>Am. J. Med. Genet. Part A</source><year>2015</year><volume>167</volume><fpage>2272</fpage><lpage>2281</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.37172</pub-id><?supplied-pmid 26069231?><pub-id pub-id-type="pmid">26069231</pub-id></element-citation></ref><ref id="B59-ijms-19-03063"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Ruijter</surname><given-names>J.</given-names></name><name><surname>Maas</surname><given-names>M.</given-names></name><name><surname>Janssen</surname><given-names>A.</given-names></name><name><surname>Wijburg</surname><given-names>F.A.</given-names></name></person-group><article-title>High prevalence of femoral head necrosis in Mucopolysaccharidosis type III (Sanfilippo disease): A national, observational, cross-sectional study</article-title><source>Mol. Genet. Metab.</source><year>2013</year><volume>109</volume><fpage>49</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.ymgme.2013.03.004</pub-id><?supplied-pmid 23541797?><pub-id pub-id-type="pmid">23541797</pub-id></element-citation></ref><ref id="B60-ijms-19-03063"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>K.K.</given-names></name><name><surname>Karol</surname><given-names>L.A.</given-names></name><name><surname>White</surname><given-names>D.R.</given-names></name><name><surname>Hale</surname><given-names>S.</given-names></name></person-group><article-title>Musculoskeletal Manifestations of Sanfilippo Syndrome (Mucopolysaccharidosis Type III)</article-title><source>J. Pediatr. Orthop.</source><year>2011</year><volume>31</volume><fpage>594</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1097/BPO.0b013e31821f5ee9</pub-id><?supplied-pmid 21654471?><pub-id pub-id-type="pmid">21654471</pub-id></element-citation></ref><ref id="B61-ijms-19-03063"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S.J.</given-names></name><name><surname>Li</surname><given-names>Y.W.</given-names></name><name><surname>Wang</surname><given-names>T.R.</given-names></name><name><surname>Hsu</surname><given-names>J.C.</given-names></name></person-group><article-title>Bony changes in common mucopolysaccharidoses</article-title><source>Acta Paediatr. Sin.</source><year>1996</year><volume>37</volume><fpage>178</fpage><lpage>184</lpage><?supplied-pmid 8755171?><pub-id pub-id-type="pmid">8755171</pub-id></element-citation></ref><ref id="B62-ijms-19-03063"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haddad</surname><given-names>F.S.</given-names></name><name><surname>Jones</surname><given-names>D.H.</given-names></name><name><surname>Vellodi</surname><given-names>A.</given-names></name><name><surname>Kane</surname><given-names>N.</given-names></name><name><surname>Pitt</surname><given-names>M.C.</given-names></name></person-group><article-title>Carpal tunnel syndrome in the mucopolysaccharidoses and mucolipidoses</article-title><source>J. Bone Joint Surg. Br.</source><year>1997</year><volume>79</volume><fpage>576</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1302/0301-620X.79B4.7547</pub-id><?supplied-pmid 9250742?><pub-id pub-id-type="pmid">9250742</pub-id></element-citation></ref><ref id="B63-ijms-19-03063"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raiman</surname><given-names>J.</given-names></name><name><surname>D&#x02019;Aco</surname><given-names>K.</given-names></name></person-group><article-title>An 8-Year-Old Girl with a History of Stiff and Painful Joints</article-title><source>Pediatr. Ann.</source><year>2014</year><volume>43</volume><fpage>307</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.3928/00904481-20140723-05</pub-id><?supplied-pmid 25102484?><pub-id pub-id-type="pmid">25102484</pub-id></element-citation></ref><ref id="B64-ijms-19-03063"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jurecka</surname><given-names>A.</given-names></name><name><surname>Marucha</surname><given-names>J.</given-names></name><name><surname>Jurkiewicz</surname><given-names>E.</given-names></name><name><surname>R&#x000f3;&#x0017c;d&#x0017c;y&#x00144;ska-&#x0015a;wi&#x00105;tkowska</surname><given-names>A.</given-names></name><name><surname>Tylki-Szyma&#x00144;ska</surname><given-names>A.</given-names></name></person-group><article-title>Enzyme replacement therapy in an attenuated case of mucopolysaccharidosis type I (Scheie syndrome): A 6.5-year detailed follow-up</article-title><source>Pediatr. Neurol.</source><year>2012</year><volume>47</volume><fpage>461</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2012.08.010</pub-id><?supplied-pmid 23127271?><pub-id pub-id-type="pmid">23127271</pub-id></element-citation></ref><ref id="B65-ijms-19-03063"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Meir</surname><given-names>N.</given-names></name><name><surname>De Smet</surname><given-names>L.</given-names></name></person-group><article-title>Carpal tunnel syndrome in children</article-title><source>Acta Orthop. Belg.</source><year>2003</year><volume>69</volume><fpage>387</fpage><lpage>395</lpage><?supplied-pmid 14648946?><pub-id pub-id-type="pmid">14648946</pub-id></element-citation></ref><ref id="B66-ijms-19-03063"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ransford</surname><given-names>A.O.</given-names></name><name><surname>Crockard</surname><given-names>H.A.</given-names></name><name><surname>Stevens</surname><given-names>J.M.</given-names></name><name><surname>Modaghegh</surname><given-names>S.</given-names></name></person-group><article-title>Occipito-atlanto-axial fusion in Morquio-Brailsford syndrome. A ten-year experience</article-title><source>J. Bone Joint Surg. Br.</source><year>1996</year><volume>78</volume><fpage>307</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1302/0301-620X.78B2.0780307</pub-id><?supplied-pmid 8666648?><pub-id pub-id-type="pmid">8666648</pub-id></element-citation></ref><ref id="B67-ijms-19-03063"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valayannopoulos</surname><given-names>V.</given-names></name><name><surname>Nicely</surname><given-names>H.</given-names></name><name><surname>Harmatz</surname><given-names>P.</given-names></name><name><surname>Turbeville</surname><given-names>S.</given-names></name></person-group><article-title>Mucopolysaccharidosis VI</article-title><source>Orphanet J. Rare Dis.</source><year>2010</year><volume>5</volume><fpage>5</fpage><pub-id pub-id-type="doi">10.1186/1750-1172-5-5</pub-id><?supplied-pmid 20385007?><pub-id pub-id-type="pmid">20385007</pub-id></element-citation></ref><ref id="B68-ijms-19-03063"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parkinson</surname><given-names>K.N.</given-names></name><name><surname>Dickinson</surname><given-names>H.O.</given-names></name><name><surname>Arnaud</surname><given-names>C.</given-names></name><name><surname>Lyons</surname><given-names>A.</given-names></name><name><surname>Colver</surname><given-names>A.</given-names></name><name><surname>Beckung</surname><given-names>E.</given-names></name></person-group><article-title>Pain in young people aged 13 to 17 years with cerebral palsy: Cross-sectional, multicentre European study</article-title><source>Arch. Dis. Child.</source><year>2013</year><volume>98</volume><fpage>434</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1136/archdischild-2012-303482</pub-id><?supplied-pmid 23606716?><pub-id pub-id-type="pmid">23606716</pub-id></element-citation></ref><ref id="B69-ijms-19-03063"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parkinson</surname><given-names>K.</given-names></name><name><surname>Gibson</surname><given-names>L.</given-names></name><name><surname>Dickinson</surname><given-names>H.</given-names></name><name><surname>Colver</surname><given-names>A.</given-names></name></person-group><article-title>Pain in children with cerebral palsy: A cross-sectional multicentre European study</article-title><source>Acta Paediatr.</source><year>2010</year><volume>99</volume><fpage>446</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1111/j.1651-2227.2009.01626.x</pub-id><?supplied-pmid 20003101?><pub-id pub-id-type="pmid">20003101</pub-id></element-citation></ref><ref id="B70-ijms-19-03063"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penner</surname><given-names>M.</given-names></name><name><surname>Xie</surname><given-names>W.Y.</given-names></name><name><surname>Binepal</surname><given-names>N.</given-names></name><name><surname>Switzer</surname><given-names>L.</given-names></name><name><surname>Fehlings</surname><given-names>D.</given-names></name></person-group><article-title>Characteristics of Pain in Children and Youth With Cerebral Palsy</article-title><source>Pediatrics</source><year>2013</year><volume>132</volume><fpage>e407</fpage><lpage>e413</lpage><pub-id pub-id-type="doi">10.1542/peds.2013-0224</pub-id><?supplied-pmid 23858420?><pub-id pub-id-type="pmid">23858420</pub-id></element-citation></ref><ref id="B71-ijms-19-03063"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breau</surname><given-names>L.M.</given-names></name><name><surname>Camfield</surname><given-names>C.S.</given-names></name><name><surname>McGrath</surname><given-names>P.J.</given-names></name><name><surname>Finley</surname><given-names>G.A.</given-names></name></person-group><article-title>The Incidence of Pain in Children with Severe Cognitive Impairments</article-title><source>Arch. Pediatr. Adolesc. Med.</source><year>2003</year><volume>157</volume><fpage>1219</fpage><lpage>1226</lpage><pub-id pub-id-type="doi">10.1001/archpedi.157.12.1219</pub-id><?supplied-pmid 14662579?><pub-id pub-id-type="pmid">14662579</pub-id></element-citation></ref><ref id="B72-ijms-19-03063"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malviya</surname><given-names>S.</given-names></name><name><surname>Voepel-Lewis</surname><given-names>T.</given-names></name><name><surname>Burke</surname><given-names>C.</given-names></name><name><surname>Merkel</surname><given-names>S.</given-names></name><name><surname>Tait</surname><given-names>A.R.</given-names></name></person-group><article-title>The Revised Flacc Observational Pain Tool: Improved reliability and validity for pain assessment in children with cognitive impairment</article-title><source>Pediatr. Anesth.</source><year>2006</year><volume>16</volume><fpage>258</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1111/j.1460-9592.2005.01773.x</pub-id><?supplied-pmid 16490089?><pub-id pub-id-type="pmid">16490089</pub-id></element-citation></ref><ref id="B73-ijms-19-03063"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen-Lim</surname><given-names>M.L.</given-names></name><name><surname>Zarnowsky</surname><given-names>C.</given-names></name><name><surname>Green</surname><given-names>R.</given-names></name><name><surname>Shaffer</surname><given-names>S.</given-names></name><name><surname>Holtzer</surname><given-names>B.</given-names></name><name><surname>Ely</surname><given-names>E.</given-names></name></person-group><article-title>Optimizing the Assessment of Pain in Children Who Are Cognitively Impaired Through the Quality Improvement Process</article-title><source>J. Pediatr. Nurs.</source><year>2012</year><volume>27</volume><fpage>750</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.1016/j.pedn.2012.03.023</pub-id><?supplied-pmid 22497741?><pub-id pub-id-type="pmid">22497741</pub-id></element-citation></ref><ref id="B74-ijms-19-03063"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bjoraker</surname><given-names>K.J.</given-names></name><name><surname>Delaney</surname><given-names>K.</given-names></name><name><surname>Peters</surname><given-names>C.</given-names></name><name><surname>Krivit</surname><given-names>W.</given-names></name><name><surname>Shapiro</surname><given-names>E.G.</given-names></name></person-group><article-title>Long-term outcomes of adaptive functions for children with mucopolysaccharidosis I (Hurler syndrome) treated with hematopoietic stem cell transplantation</article-title><source>J. Dev. Behav. Pediatr.</source><year>2006</year><volume>27</volume><fpage>290</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1097/00004703-200608000-00002</pub-id><?supplied-pmid 16906003?><pub-id pub-id-type="pmid">16906003</pub-id></element-citation></ref><ref id="B75-ijms-19-03063"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunin-Batson</surname><given-names>A.S.</given-names></name><name><surname>Shapiro</surname><given-names>E.G.</given-names></name><name><surname>Rudser</surname><given-names>K.D.</given-names></name><name><surname>Lavery</surname><given-names>C.A.</given-names></name><name><surname>Bjoraker</surname><given-names>K.J.</given-names></name><name><surname>Jones</surname><given-names>S.A.</given-names></name><name><surname>Wynn</surname><given-names>R.F.</given-names></name><name><surname>Vellodi</surname><given-names>A.</given-names></name><name><surname>Tolar</surname><given-names>J.</given-names></name><name><surname>Orchard</surname><given-names>P.J.</given-names></name><etal/></person-group><article-title>Long-Term Cognitive and Functional Outcomes in Children with Mucopolysaccharidosis (MPS)-IH (Hurler Syndrome) Treated with Hematopoietic Cell Transplantation</article-title><source>JIMD Rep.</source><year>2015</year><volume>29</volume><fpage>95</fpage><lpage>102</lpage></element-citation></ref><ref id="B76-ijms-19-03063"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harmatz</surname><given-names>P.R.</given-names></name><name><surname>Mengel</surname><given-names>E.</given-names></name><name><surname>Geberhiwot</surname><given-names>T.</given-names></name><name><surname>Muschol</surname><given-names>N.</given-names></name><name><surname>Hendriksz</surname><given-names>C.J.</given-names></name><name><surname>Burton</surname><given-names>B.K.</given-names></name><name><surname>Jameson</surname><given-names>E.</given-names></name><name><surname>Berger</surname><given-names>K.I.</given-names></name><name><surname>Jester</surname><given-names>A.</given-names></name><name><surname>Treadwell</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Impact of elosulfase alfa in patients with morquio A syndrome who have limited ambulation: An open-label, phase 2 study</article-title><source>Am. J. Med. Genet. A</source><year>2017</year><volume>173</volume><fpage>375</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.38014</pub-id><?supplied-pmid 27774754?><pub-id pub-id-type="pmid">27774754</pub-id></element-citation></ref><ref id="B77-ijms-19-03063"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tylki-Szymanska</surname><given-names>A.</given-names></name><name><surname>Marucha</surname><given-names>J.</given-names></name><name><surname>Jurecka</surname><given-names>A.</given-names></name><name><surname>Syczewska</surname><given-names>M.</given-names></name><name><surname>Czartoryska</surname><given-names>B.</given-names></name></person-group><article-title>Efficacy of recombinant human &#x003b1;-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients</article-title><source>J. Inherit. Metab. Dis.</source><year>2010</year><volume>33</volume><fpage>151</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1007/s10545-010-9059-9</pub-id><?supplied-pmid 20217237?><pub-id pub-id-type="pmid">20217237</pub-id></element-citation></ref><ref id="B78-ijms-19-03063"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wraith</surname><given-names>J.E.</given-names></name><name><surname>Clarke</surname><given-names>L.A.</given-names></name><name><surname>Beck</surname><given-names>M.</given-names></name><name><surname>Kolodny</surname><given-names>E.H.</given-names></name><name><surname>Pastores</surname><given-names>G.M.</given-names></name><name><surname>Muenzer</surname><given-names>J.</given-names></name><name><surname>Rapoport</surname><given-names>D.M.</given-names></name><name><surname>Berger</surname><given-names>K.I.</given-names></name><name><surname>Swiedler</surname><given-names>S.J.</given-names></name><name><surname>Kakkis</surname><given-names>E.D.</given-names></name><etal/></person-group><article-title>Enzyme replacement therapy for mucopolysaccharidosis I: A randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase)</article-title><source>J. Pediatr.</source><year>2004</year><volume>144</volume><fpage>581</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2004.01.046</pub-id><?supplied-pmid 15126990?><pub-id pub-id-type="pmid">15126990</pub-id></element-citation></ref><ref id="B79-ijms-19-03063"><label>79.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>U.S, Food and Drug Administration</collab></person-group><article-title>Center for drug Evakuation and Research</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="www.accessdata.fda.gov/scripts/cder/drugsatfda">www.accessdata.fda.gov/scripts/cder/drugsatfda</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2018-10-06">(accessed on 6 October 2018)</date-in-citation></element-citation></ref><ref id="B80-ijms-19-03063"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harmatz</surname><given-names>P.</given-names></name><name><surname>Whitley</surname><given-names>C.B.</given-names></name><name><surname>Waber</surname><given-names>L.</given-names></name><name><surname>Pais</surname><given-names>R.</given-names></name><name><surname>Steiner</surname><given-names>R.</given-names></name><name><surname>Plecko</surname><given-names>B.</given-names></name><name><surname>Kaplan</surname><given-names>P.</given-names></name><name><surname>Simon</surname><given-names>J.</given-names></name><name><surname>Butensky</surname><given-names>E.</given-names></name><name><surname>Hopwood</surname><given-names>J.H.</given-names></name><etal/></person-group><article-title>Enzyme replacement therapy in mucopolisaccaridosis VI</article-title><source>J. Pediatr.</source><year>2004</year><volume>144</volume><fpage>574</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2004.03.018</pub-id><?supplied-pmid 15126989?><pub-id pub-id-type="pmid">15126989</pub-id></element-citation></ref><ref id="B81-ijms-19-03063"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polgreen</surname><given-names>L.E.</given-names></name><name><surname>Vehe</surname><given-names>R.K.</given-names></name><name><surname>Rudser</surname><given-names>K.</given-names></name><name><surname>Kunin-Batson</surname><given-names>A.</given-names></name><name><surname>Utz</surname><given-names>J.J.</given-names></name><name><surname>Dickson</surname><given-names>P.</given-names></name><name><surname>Shapiro</surname><given-names>E.</given-names></name><name><surname>Whitley</surname><given-names>C.B.</given-names></name></person-group><article-title>Elevated TNF-&#x003b1; is associated with pain and physical disability in mucopolysaccharidosis types I, II, and VI</article-title><source>Mol. Genet. Metab.</source><year>2016</year><volume>117</volume><fpage>427</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1016/j.ymgme.2016.01.012</pub-id><?supplied-pmid 26873528?><pub-id pub-id-type="pmid">26873528</pub-id></element-citation></ref><ref id="B82-ijms-19-03063"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauer</surname><given-names>J.M.</given-names></name><name><surname>Wical</surname><given-names>B.S.</given-names></name><name><surname>Charnas</surname><given-names>L.</given-names></name></person-group><article-title>Gabapentin successfully manages chronic unexplained irritabily in children with severe neurologi impairment</article-title><source>Pediatrics</source><year>2007</year><volume>119</volume><fpage>e519</fpage><pub-id pub-id-type="doi">10.1542/peds.2006-1609</pub-id><?supplied-pmid 17272610?><pub-id pub-id-type="pmid">17272610</pub-id></element-citation></ref><ref id="B83-ijms-19-03063"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauer</surname><given-names>J.M.</given-names></name></person-group><article-title>Identifying and managing sources of pain and distress in children with neurological impairment</article-title><source>Pediatr. Ann.</source><year>2010</year><volume>39</volume><fpage>198</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.3928/00904481-20100318-04</pub-id><?supplied-pmid 20411897?><pub-id pub-id-type="pmid">20411897</pub-id></element-citation></ref><ref id="B84-ijms-19-03063"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>M.E.</given-names></name><name><surname>Campbell</surname><given-names>F.</given-names></name></person-group><article-title>Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials</article-title><source>Br. J. Clin. Pharmacol.</source><year>2011</year><volume>72</volume><fpage>735</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2011.03970.x</pub-id><?supplied-pmid 21426373?><pub-id pub-id-type="pmid">21426373</pub-id></element-citation></ref><ref id="B85-ijms-19-03063"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahn</surname><given-names>E.J.</given-names></name><name><surname>Hohmann</surname><given-names>A.G.</given-names></name></person-group><article-title>Cannabinoids as pharmacotherapies for neuropathic pain: From the bench to the bedside</article-title><source>Neurotherapeutics</source><year>2009</year><volume>6</volume><fpage>713</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1016/j.nurt.2009.08.002</pub-id><?supplied-pmid 19789075?><pub-id pub-id-type="pmid">19789075</pub-id></element-citation></ref><ref id="B86-ijms-19-03063"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ray</surname><given-names>A.P.</given-names></name><name><surname>Griggs</surname><given-names>L.</given-names></name><name><surname>Darmani</surname><given-names>N.A.</given-names></name></person-group><article-title>Delta 9-tetrahydrocannabinol suppresses vomiting behavior and Fos expression in both acute and delayed phases of cisplatin-induced emesis in the least shrew</article-title><source>Behav. Brain Res.</source><year>2009</year><volume>196</volume><fpage>30</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.bbr.2008.07.028</pub-id><?supplied-pmid 18721829?><pub-id pub-id-type="pmid">18721829</pub-id></element-citation></ref><ref id="B87-ijms-19-03063"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malfitano</surname><given-names>A.M.</given-names></name><name><surname>Proto</surname><given-names>M.C.</given-names></name><name><surname>Bifulco</surname><given-names>M.</given-names></name></person-group><article-title>Cannabinoids in the management of spasticity associated with multiple sclerosis</article-title><source>Neuropsychiatr. Dis. Treat.</source><year>2008</year><volume>4</volume><fpage>847</fpage><lpage>853</lpage><?supplied-pmid 19183777?><pub-id pub-id-type="pmid">19183777</pub-id></element-citation></ref><ref id="B88-ijms-19-03063"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abrams</surname><given-names>D.I.</given-names></name><name><surname>Jay</surname><given-names>C.A.</given-names></name><name><surname>Shade</surname><given-names>S.B.</given-names></name><name><surname>Vizoso</surname><given-names>H.</given-names></name><name><surname>Reda</surname><given-names>H.</given-names></name><name><surname>Press</surname><given-names>S.</given-names></name><name><surname>Kelly</surname><given-names>M.E.</given-names></name><name><surname>Rowbotham</surname><given-names>M.C.</given-names></name><name><surname>Petersen</surname><given-names>K.L.</given-names></name></person-group><article-title>Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial</article-title><source>Neurology</source><year>2007</year><volume>68</volume><fpage>515</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000253187.66183.9c</pub-id><?supplied-pmid 17296917?><pub-id pub-id-type="pmid">17296917</pub-id></element-citation></ref><ref id="B89-ijms-19-03063"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>T.E.</given-names></name><name><surname>Bruce</surname><given-names>B.K.</given-names></name><name><surname>Weiss</surname><given-names>K.E.</given-names></name><name><surname>Rummans</surname><given-names>T.A.</given-names></name><name><surname>Bostwick</surname><given-names>J.M.</given-names></name></person-group><article-title>Marijuana and chronic nonmalignant pain in adolescents</article-title><source>Mayo Clin. Proc.</source><year>2013</year><volume>88</volume><fpage>647</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1016/j.mayocp.2013.04.018</pub-id><?supplied-pmid 23787068?><pub-id pub-id-type="pmid">23787068</pub-id></element-citation></ref><ref id="B90-ijms-19-03063"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>M.A.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Shapiro</surname><given-names>S.</given-names></name><name><surname>Collet</surname><given-names>J.P.</given-names></name></person-group><article-title>Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS). COMPASS study team</article-title><source>J. Pain</source><year>2015</year><volume>16</volume><fpage>1233</fpage><lpage>1242</lpage><pub-id pub-id-type="doi">10.1016/j.jpain.2015.07.014</pub-id><?supplied-pmid 26385201?><pub-id pub-id-type="pmid">26385201</pub-id></element-citation></ref><ref id="B91-ijms-19-03063"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asthon</surname><given-names>C.H.</given-names></name></person-group><article-title>Adverse effects of cannabis and cannabinoids</article-title><source>Br. J. Anaesth.</source><year>1999</year><volume>83</volume><fpage>637</fpage><lpage>649</lpage><pub-id pub-id-type="pmid">10673884</pub-id></element-citation></ref><ref id="B92-ijms-19-03063"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bottorff</surname><given-names>J.L.</given-names></name><name><surname>Johnson</surname><given-names>J.L.</given-names></name><name><surname>Moffat</surname><given-names>B.M.</given-names></name><name><surname>Mulvogue</surname><given-names>T.</given-names></name></person-group><article-title>Relief-oriented use of marijuana by teens</article-title><source>Subst. Abuse Treat. Prev. Policy</source><year>2009</year><volume>4</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/1747-597X-4-7</pub-id><?supplied-pmid 19389223?><pub-id pub-id-type="pmid">19389223</pub-id></element-citation></ref><ref id="B93-ijms-19-03063"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>L.L.</given-names></name><name><surname>Vowles</surname><given-names>K.E.</given-names></name><name><surname>Eccleston</surname><given-names>C.</given-names></name></person-group><article-title>The impact of adolescent chronic pain on functioning: Disentangling the complex role of anxiety</article-title><source>J. Pain</source><year>2010</year><volume>11</volume><fpage>1039</fpage><lpage>1046</lpage><pub-id pub-id-type="doi">10.1016/j.jpain.2009.09.009</pub-id><?supplied-pmid 20015706?><pub-id pub-id-type="pmid">20015706</pub-id></element-citation></ref><ref id="B94-ijms-19-03063"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gauntlett-Gilbert</surname><given-names>J.</given-names></name><name><surname>Eccleston</surname><given-names>C.</given-names></name></person-group><article-title>Disability in adolescents with chronic pain: Patterns and predictors across different domains of functioning</article-title><source>Pain</source><year>2007</year><volume>131</volume><fpage>132</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2006.12.021</pub-id><?supplied-pmid 17267129?><pub-id pub-id-type="pmid">17267129</pub-id></element-citation></ref><ref id="B95-ijms-19-03063"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaczynski</surname><given-names>K.J.</given-names></name><name><surname>Simons</surname><given-names>L.E.</given-names></name><name><surname>Lewis Claar</surname><given-names>R.</given-names></name></person-group><article-title>Anxiety, coping, and disability: A test of mediation in a pediatric chronic pain sample</article-title><source>J. Pediatr. Psychol.</source><year>2011</year><volume>36</volume><fpage>932</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.1093/jpepsy/jsr024</pub-id><?supplied-pmid 21551124?><pub-id pub-id-type="pmid">21551124</pub-id></element-citation></ref><ref id="B96-ijms-19-03063"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravindran</surname><given-names>A.V.</given-names></name><name><surname>da Silva</surname><given-names>T.L.</given-names></name></person-group><article-title>Complementary and alternative therapies as add-on to pharmacotherapy for mood and anxiety disorders: A systematic review</article-title><source>J. Affect. Disord.</source><year>2013</year><volume>150</volume><fpage>707</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2013.05.042</pub-id><?supplied-pmid 23769610?><pub-id pub-id-type="pmid">23769610</pub-id></element-citation></ref><ref id="B97-ijms-19-03063"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>K.L.</given-names></name></person-group><article-title>Chronic pain management: Nonpharmacological therapies for chronic pain</article-title><source>FP Essent.</source><year>2015</year><volume>432</volume><fpage>21</fpage><lpage>26</lpage><?supplied-pmid 25970869?><pub-id pub-id-type="pmid">25970869</pub-id></element-citation></ref><ref id="B98-ijms-19-03063"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eccleston</surname><given-names>C.</given-names></name><name><surname>Palermo</surname><given-names>T.M.</given-names></name><name><surname>Williams</surname><given-names>A.C.</given-names></name><name><surname>Lewandowski Holley</surname><given-names>A.</given-names></name><name><surname>Morley</surname><given-names>S.</given-names></name><name><surname>Fisher</surname><given-names>E.</given-names></name><name><surname>Law</surname><given-names>E.</given-names></name></person-group><article-title>Psychological therapies for the management of chronic and recurrent pain in children and adolescents</article-title><source>Cochrane Database Syst. Rev.</source><year>2014</year><volume>2</volume><fpage>CD003968</fpage></element-citation></ref><ref id="B99-ijms-19-03063"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>N.C.</given-names></name></person-group><article-title>Audiovisual distraction for pain relief in paediatric inpatients: A crossover study</article-title><source>Eur. J. Pain</source><year>2016</year><pub-id pub-id-type="doi">10.1002/ejp.915</pub-id><?supplied-pmid 27461092?><pub-id pub-id-type="pmid">27461092</pub-id></element-citation></ref><ref id="B100-ijms-19-03063"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbarin</surname><given-names>O.A.</given-names></name><name><surname>Whitten</surname><given-names>C.F.</given-names></name><name><surname>Bond</surname><given-names>S.</given-names></name><name><surname>Conner-Warren</surname><given-names>R.</given-names></name></person-group><article-title>The social and cultural context of coping with sickle cell disease: II. The role of financial hardship in adjustment to sickle cell disease</article-title><source>J. Black Psychol.</source><year>1999</year><volume>25</volume><fpage>294</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1177/0095798499025003003</pub-id></element-citation></ref><ref id="B101-ijms-19-03063"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winston</surname><given-names>C.A.</given-names></name><name><surname>Leshner</surname><given-names>P.</given-names></name><name><surname>Kramer</surname><given-names>J.</given-names></name><name><surname>Allen</surname><given-names>G.</given-names></name></person-group><article-title>Overcoming Barriers to Access and Utilization of Hospice and Palliative Care Services in African-American Communities</article-title><source>Omega J. Death Dying.</source><year>2004</year><volume>50</volume><fpage>151</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.2190/QQKG-EPFA-A2FN-GHVL</pub-id></element-citation></ref><ref id="B102-ijms-19-03063"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rupp</surname><given-names>T.</given-names></name><name><surname>Delaney</surname><given-names>K.A.</given-names></name></person-group><article-title>Inadequate analgesia in emergency medicine</article-title><source>Ann. Emerg. Med.</source><year>2004</year><volume>43</volume><fpage>494</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1016/j.annemergmed.2003.11.019</pub-id><?supplied-pmid 15039693?><pub-id pub-id-type="pmid">15039693</pub-id></element-citation></ref><ref id="B103-ijms-19-03063"><label>103.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source>Acupuncture Review and Analysis of Reports on Controlled Clinical Trials</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Cervia, Italy</publisher-loc><year>2003</year></element-citation></ref><ref id="B104-ijms-19-03063"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>L.F.</given-names></name></person-group><article-title>Involvement of endogenous opioid peptides in acupuncture analgesia</article-title><source>Pain</source><year>1987</year><volume>31</volume><fpage>99</fpage><lpage>121</lpage><?supplied-pmid 3320881?><pub-id pub-id-type="pmid">3320881</pub-id></element-citation></ref><ref id="B105-ijms-19-03063"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golianu</surname><given-names>B.</given-names></name><name><surname>Ming Yeh</surname><given-names>A.</given-names></name><name><surname>Brooks</surname><given-names>M.</given-names></name></person-group><article-title>Acupuncture for pediatric pain</article-title><source>Children</source><year>2014</year><volume>1</volume><fpage>134</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.3390/children1020134</pub-id><?supplied-pmid 27417472?><pub-id pub-id-type="pmid">27417472</pub-id></element-citation></ref><ref id="B106-ijms-19-03063"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeltzer</surname><given-names>L.K.</given-names></name><name><surname>Tsao</surname><given-names>J.C.</given-names></name><name><surname>Stelling</surname><given-names>C.</given-names></name><name><surname>Powers</surname><given-names>M.</given-names></name><name><surname>Levy</surname><given-names>S.</given-names></name><name><surname>Waterhouse</surname><given-names>M.</given-names></name></person-group><article-title>A phase I study on the feasibility and acceptability of an acupuncture/hypnosis intervention for chronic pediatric pain</article-title><source>J. Pain Symptom Manag.</source><year>2002</year><volume>24</volume><fpage>437</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1016/S0885-3924(02)00506-7</pub-id></element-citation></ref><ref id="B107-ijms-19-03063"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yonehara</surname><given-names>N.</given-names></name></person-group><article-title>Influence of serotonin receptor antagonists on substance P and serotonin release evoked by tooth pulp stimulation with electro-acupuncture in the trigeminal nucleus cudalis of the rabbit</article-title><source>Neurosci. Res.</source><year>2001</year><volume>40</volume><fpage>45</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/S0168-0102(01)00207-3</pub-id><pub-id pub-id-type="pmid">11311404</pub-id></element-citation></ref><ref id="B108-ijms-19-03063"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>K.H.</given-names></name><name><surname>Jung</surname><given-names>P.</given-names></name><name><surname>Sang</surname><given-names>J.B.</given-names></name><name><surname>Kim</surname><given-names>J.H.</given-names></name><name><surname>Hwang</surname><given-names>B.G.</given-names></name><name><surname>Min</surname><given-names>B.I.</given-names></name><name><surname>Park</surname><given-names>D.S.</given-names></name><name><surname>Na</surname><given-names>H.S.</given-names></name></person-group><article-title>Effects of electroacupuncture on cold allodynia in a rat model of neuropathic pain: Mediation by spinal adrenergic and serotonergic receptors</article-title><source>Exp. Neurol.</source><year>2005</year><volume>195</volume><fpage>430</fpage><lpage>436</lpage><pub-id pub-id-type="pmid">16054138</pub-id></element-citation></ref><ref id="B109-ijms-19-03063"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mungu&#x000ed;a-Izquierdo</surname><given-names>D.</given-names></name><name><surname>Legaz-Arrese</surname><given-names>A.</given-names></name></person-group><article-title>Exercise in warm water decreases pain and improves cognitive function in middle-aged women with fibromyalgia</article-title><source>Clin. Exp. Rheumatol.</source><year>2007</year><volume>25</volume><fpage>823</fpage><lpage>830</lpage><?supplied-pmid 18173915?><pub-id pub-id-type="pmid">18173915</pub-id></element-citation></ref><ref id="B110-ijms-19-03063"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kober</surname><given-names>A.</given-names></name><name><surname>Scheck</surname><given-names>T.</given-names></name><name><surname>Fulesdi</surname><given-names>B.</given-names></name><name><surname>Liera</surname><given-names>F.</given-names></name><name><surname>Vlach</surname><given-names>W.</given-names></name><name><surname>Friedman</surname><given-names>A.</given-names></name><name><surname>Sessler</surname><given-names>D.I.</given-names></name></person-group><article-title>Effectiveness of resistive heating compared with passive warming in treating hypothermia associated with minor trauma: A randomized trial</article-title><source>Mayo Clin. Proc.</source><year>2001</year><volume>76</volume><fpage>369</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1016/S0025-6196(11)62384-7</pub-id><pub-id pub-id-type="pmid">11322352</pub-id></element-citation></ref><ref id="B111-ijms-19-03063"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beider</surname><given-names>S.</given-names></name><name><surname>Moyer</surname><given-names>C.A.</given-names></name></person-group><article-title>Randomized controlled trials of pediatric massage: A review</article-title><source>Evid. Based Complement. Altern. Med.</source><year>2007</year><volume>4</volume><fpage>23</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1093/ecam/nel068</pub-id><?supplied-pmid 17342238?><pub-id pub-id-type="pmid">17342238</pub-id></element-citation></ref><ref id="B112-ijms-19-03063"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayden</surname><given-names>J.A.</given-names></name><name><surname>Mior</surname><given-names>S.A.</given-names></name><name><surname>Verhoef</surname><given-names>M.J.</given-names></name></person-group><article-title>Evaluation of chiropractic management of pediatric patients with low back pain: A prospective cohort study</article-title><source>J. Manip. Physiol. Ther.</source><year>2003</year><volume>26</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1067/mmt.2003.11</pub-id><?supplied-pmid 12532132?><pub-id pub-id-type="pmid">12532132</pub-id></element-citation></ref><ref id="B113-ijms-19-03063"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenny</surname><given-names>D.T.</given-names></name><name><surname>Faunce</surname><given-names>G.</given-names></name></person-group><article-title>The impact of group singing on mood, coping, and perceived pain in chronic pain patients attending a multidisciplinary pain clinic</article-title><source>J. Music Ther.</source><year>2004</year><volume>41</volume><fpage>241</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1093/jmt/41.3.241</pub-id><?supplied-pmid 15327342?><pub-id pub-id-type="pmid">15327342</pub-id></element-citation></ref><ref id="B114-ijms-19-03063"><label>114.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jeffery</surname><given-names>M.M.</given-names></name><name><surname>Butler</surname><given-names>M.</given-names></name><name><surname>Stark</surname><given-names>A.</given-names></name><name><surname>Kane</surname><given-names>R.L.</given-names></name></person-group><source>Multidisciplinary Pain Programs for Chronic Noncancer Pain [Internet]</source><publisher-name>Agency for Healthcare Research and Quality (US)</publisher-name><publisher-loc>Rockville, MD, USA</publisher-loc><year>2011</year><gov>Sep. Report No.: 11-EHC064-EF. AHRQ Comparative Effectiveness Technical Briefs</gov></element-citation></ref><ref id="B115-ijms-19-03063"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braun</surname><given-names>C.</given-names></name><name><surname>Stangler</surname><given-names>T.</given-names></name><name><surname>Narveson</surname><given-names>J.</given-names></name><name><surname>Pettingell</surname><given-names>S.</given-names></name></person-group><article-title>Animal-assisted therapy as a pain relief intervention for children</article-title><source>Complement. Ther. Clin. Pract.</source><year>2009</year><volume>15</volume><fpage>105</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.ctcp.2009.02.008</pub-id><?supplied-pmid 19341990?><pub-id pub-id-type="pmid">19341990</pub-id></element-citation></ref><ref id="B116-ijms-19-03063"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sobo</surname><given-names>E.J.</given-names></name><name><surname>Eng</surname><given-names>B.</given-names></name><name><surname>Kassity-Krich</surname><given-names>N.</given-names></name></person-group><article-title>Canine visitation (pet) therapy: Pilot data on decreases in child pain perception</article-title><source>J. Holist. Nurs.</source><year>2006</year><volume>24</volume><fpage>51</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1177/0898010105280112</pub-id><?supplied-pmid 16449747?><pub-id pub-id-type="pmid">16449747</pub-id></element-citation></ref><ref id="B117-ijms-19-03063"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gautam</surname><given-names>D.</given-names></name><name><surname>Malhotra</surname><given-names>R.</given-names></name></person-group><article-title>Total hip arthroplasty in Hurler syndrome&#x02014;8 years follow up&#x02014;A case report with review of literature</article-title><source>J. Orthop.</source><year>2018</year><volume>15</volume><fpage>111</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1016/j.jor.2018.01.036</pub-id><?supplied-pmid 29657451?><pub-id pub-id-type="pmid">29657451</pub-id></element-citation></ref><ref id="B118-ijms-19-03063"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van der Linden</surname><given-names>M.H.</given-names></name><name><surname>Kruyt</surname><given-names>M.C.</given-names></name><name><surname>Sakkers</surname><given-names>R.J.</given-names></name><name><surname>de Koning</surname><given-names>T.J.</given-names></name><name><surname>Oner</surname><given-names>F.C.</given-names></name><name><surname>Castelein</surname><given-names>R.M.</given-names></name></person-group><article-title>Orthopaedic management of Hurler&#x02019;s disease after hematopoietic stem cell transplantation: A systematic review</article-title><source>J. Inherit. Metab. Dis.</source><year>2011</year><volume>34</volume><fpage>657</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1007/s10545-011-9304-x</pub-id><?supplied-pmid 21416194?><pub-id pub-id-type="pmid">21416194</pub-id></element-citation></ref><ref id="B119-ijms-19-03063"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>N.</given-names></name><name><surname>Challoumas</surname><given-names>D.</given-names></name><name><surname>Eastwood</surname><given-names>D.M.</given-names></name></person-group><article-title>Does orthopaedic surgery improve quality of life and function in patients with mucopolysaccharidoses?</article-title><source>J. Child Orthop.</source><year>2017</year><volume>11</volume><fpage>289</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1302/1863-2548.11.170042</pub-id><?supplied-pmid 28904635?><pub-id pub-id-type="pmid">28904635</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="ijms-19-03063-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">ijms-19-03063-t001_Table 1</object-id><label>Table 1</label><caption><p>Mucopolysaccharidoses (MPSs) from I to IX and their modality of inheritance, type of enzyme deficiency, and cosaminoglycans (GAGs) excreted and central nervous system (CNS) involvement.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MPS Disorder</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Eponym</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Inheritance</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Enzyme Deficiency</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">GAGS Excreted</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CNS Involvement</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MPS I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hurler/Scheie</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">alpha-<sc>l</sc>-iduronidase</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DS/HS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hurler + Hurler-Scheie &#x000b1; Scheie &#x02212;</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MPS II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hunter</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">a X-linked recessive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">iduronate-2-sulphatase</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DS/HS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Severe form + Attenuated form &#x02212;</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MPS III A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sanfilippo syndrome A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Heparan <italic>N</italic>-sulfatase</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MPS III B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sanfilippo syndrome B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>N</italic>-acetyl-a-<sc>d</sc>-glucosaminidase</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MPS III C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sanfilippo syndrome C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">acetyl-CoA: a-glucosaminide <italic>N</italic>-acetyltransferase</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MPS III D</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sanfilippo syndrome D</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>N</italic>-acetylglucosamine-6-sulfatase</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MPS IV A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Morquio A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">galactosamine-6-sulfatase deficiency</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KS/CS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MPS IV B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Morquio B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">beta-galactosidase deficiency</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MPS VI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Maroteaux-Lamy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">arylsulfatase B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MPS VII</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sly</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">b-glucuronidase</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DS/HS/C6S 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MPS IX</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hyaluronidase deficiency</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hyaluronidase deficiency hyaluronidase none</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None (2 Families described)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x000b1;</td></tr></tbody></table></table-wrap><table-wrap id="ijms-19-03063-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">ijms-19-03063-t002_Table 2</object-id><label>Table 2</label><caption><p>Paracetamol, nonsteroidal anti-inflammatory drug (NSAIDs), and opioids dosage.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Molecule</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dosage</th></tr></thead><tbody><tr><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Paracetamol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>po</italic>: 20 mg/kg initially, then 15 mg/kg every 4&#x02013;6 h<break/><italic>rectal</italic>: 30&#x02013;40 mg/kg initially, then 15&#x02013;20 mg/kg every 4&#x02013;6 h<break/><italic>ev</italic>: weight &#x0003c; 10 kg: 7.5 mg/kg every 6 h<break/>weight &#x0003e; 10 kg: 15 mg/kg every 6 h<break/>Maximum dose: 90 mg/kg/day<break/>(60 mg/kg/day if present risk factors)</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Nsaid</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Low Power</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ibuprofen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>po</italic>: &#x0003c; 6 months: 5 mg/kg every 6&#x02013;8 h<break/>&#x0003e; 6 months: 10 mg/kg every 6&#x02013;8 h<break/><italic>rectal</italic>: weight &#x0003e; 6 kg, 60 mg suppository every 8 h<break/>weight &#x0003e; 12 kg, 125 mg suppository every 8 h<break/>Maximum dose: 40 mg/kg/day</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ketoprofen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>po, rectal or ev</italic>: 3 mg/kg every 8&#x02013;12 h<break/>Maximum dose: 9 mg/kg/day</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Moderate Power</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Naproxene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>po</italic>: 5&#x02013;10 mg/kg every 8&#x02013;12 h<break/>Maximum dose: 20 mg/kg/day</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">High Power</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ketorolac</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>po</italic>: 0.2 mg/kg (max 10 mg) every 4&#x02013;6 h<break/><italic>ev, im</italic>: 0.5 mg/kg start, poi 0.2&#x02013;0.3 mg/kg every 4&#x02013;6 h<break/>Maximum dose: 3 mg/kg/day</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Indomethacin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>Po</italic>, <italic>ev</italic>: 1 mg/kg every 8 hMaximum dose: 3 mg/kg/day</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Opioids</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Weak Opioids</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Codeine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>po, rectal</italic>: 0.5&#x02013;1 mg/kg every 4&#x02013;6&#x02013;8 h<break/><italic>ATTENTION</italic>:<break/>NO if &#x0003c; 12y&#x02013;old<break/>NO for 12&#x02013;18 y-old if: <break/>-recent tonsillectomy and/or adenoidectomy;<break/>-ultra-rapid metabolizer CYP2D6;<break/>-bad respiratory function</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tramadol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">po: 0.5&#x02013;1 mg/kg every 4&#x02013;6&#x02013;8 h<break/>ev: 1 mg/kg every 3&#x02013;4 h<break/>ev continuos infusion 0.3 mg/kg/h</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Strong Opioids</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Morfina</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CLORIDRATE <italic>(ev</italic>): bolus 0.05&#x02013;0.1 mg/kg every 2&#x02013;4 h, <break/>continuos infusion 0.02&#x02013;0.03 mg/kg/h<break/>SOLFATE (<italic>po</italic>): early release: 0.15&#x02013;0.3 mg/kg every 4 h; <break/>slow release: 0.3&#x02013;0.6 mg/kg every 8&#x02013;12 h</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oxicodone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>po</italic>: 0.1&#x02013;0.2 mg/kg every 8&#x02013;12 h</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fentanyl</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>ev</italic>: bolus 1&#x02013;2 gamma/kg (max 5 gamma/kg with spontaneous breathing), continuos indfusion 0.1 gamma/kg/h<break/>Intranasal: 1&#x02013;2 gamma/kg</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Methadone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>po</italic>: 0.05&#x02013;0.1 mg/kg every 8&#x02013;12 h <break/>(schedule modifying on the basis of duration therapy)</td></tr></tbody></table></table-wrap></floats-group></article>